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Introduction 
1 Introduction 
Since the discovery of RNA interference (RNAi), small interfering RNA (siRNA) provides a 
promising option for drug development in oncology over the past decade [1]. RNAi is an 
evolutionarily conserved phenomenon for sequence-specific gene silencing among multicellular 
organisms as diverse as plants, worms, yeast and humans, in which double-stranded RNA triggers 
specific degradation of the complementary mRNA sequence to silence the expression of target 
gene [2]. Since it was found that siRNA can also invoke RNAi responses in mammalian cells [3], 
this novel strategy has rapidly become a powerful tool for sequence-specific gene silencing, with 
many lead compounds in various stages of clinical development [4]. As viral vectors are not 
compatible with the delivery of synthetic siRNA, different non-viral delivery systems have 
sparkled intense investigations [5].  
 
1.1 RNAi machinery 
In mammalian cells, siRNA sequences are produced by the ribonuclease Dicer [6]. Dicer, an 
endonuclease of the RNase III family, precisely produces RNA duplexes ~21-23 nucleotides in 
length with a dinucleotide overhang at 3' end and a monophosphate group at 5' end [7]. The siRNA 
duplex length and characteristic termini are required for efficient recognition by and integration 
into the RNA-Induced Silencing Complex (RISC) [8]. RNAi is processed when siRNA is loaded 
into RISC [8], where the strands are separated, and the antisense strand (guide strand) directs 
sequence-specific cleavage of target mRNA in a manner of Watson-Crick base pairing [9]. The 
core of the RISC complex and crucial processor of RNAi is the Argonaute protein. There are four 
human Argonaute proteins (AGO 1-4), and siRNA-induced gene silencing is mediated via AGO2 
[10]. AGO2 attaches the guide siRNA strand, extrudes the passenger strand, and then repeats 
target mRNA recognition, cleavage, and release [7]. Structurally, AGO2 has three functional 
domains: PAZ, MID, and PIWI. PIWI docking an RNase H fold is the motor for RISC’s slice 
activity [11]. For RISC loading, PAZ domain is able to specifically recognize the 3' dinucleotide 
of siRNA, and such overhang enters deep into a hydrophobic pocket of the domain [12]. At the 
same time, the 5' phosphate group inserts between the MID and PIWI domains, binding to a 
magnesium ion [13]. For guide-strand selection, both the absolute and relative stabilities of the 
base pairs at the 5' end of the two siRNA strands determine which strand participates in the RNAi 
pathway, herein Argonaute selects the one with the less thermodynamically stable 5' end as the 
guide strand and cleaves the other one. Moreover, the guide siRNA strand inside RISC can be 
repeatedly used to target other complementary mRNA sequences. Such remarkable properties 
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have rendered the synthetic siRNA molecules for the therapeutic knockdown of endogenous 
mRNA [14].  
 
1.2 Antitumoral siRNA therapeutics 
Recently, numerous novel RNAi targets for malignancies have been identified, such as for breast 
cancer (WEE1) [15], glioma (PFKFB4) [16], multiple myeloma (GSK3) [17], and pancreatic 
cancer (CHK1) [18]. By silencing important oncogene targets in cancer cells, the siRNA 
therapeutics are showing impressive potential with several clinical trials are underway [19]. These 
include TKM-080301, siG12D LODER, siRNA–EphA2–DOPC, DCR-MYC, ALN–VSP02 and 
Atu027 (Table 1.2.1), providing hope to those with limited options for cancer survival. For 
examples, the company Arbutus developed TKM-PLK1 for hepatocellular carcinoma (HCC), 
using LNPs to deliver siRNA against polo-like kinase (PLK) [20]. PLK is mostly overexpressed 
in malignant cells, and inhibition of PLK results in reduced cell division [21]. Phase I trials 
indicated a dose-dependent effect and 19.3% reduction in tumor size [22]. Moreover, KRAS gene 
is overexpressed in more than 90% of pancreatic ductal adenocarcinomas [22]. To downregulate 
the KRAS gene, the company Silenseed’s siG12D LODER is composed of polylactic glycolic 
acid as polymer matrix and an unmodified siRNA against a mutant KRAS gene, KRAS-G12D 
[22]. Phase I trials that combined siG12D LODER with chemotherapy resulted in a median 
survival of 16 months, compared with a median survival of 10–13 months for patients treated with 
only chemotherapy. More encouragingly, two patients have survived beyond 2 years [22]. siG12D 
LODER has now initiated Phase II/III trials of repeated doses every 4 months combined with 
chemotherapy [20]. As another example, EphA2 gene encoding the epithelial cell receptor 
protein–tyrosine kinase is frequently overexpressed in cancer cells and its expression level is 
related to tumor aggressiveness, tumor recurrence and survival [23]. In MD Anderson Cancer 
Center, Phase I study in 40 advanced solid tumors with a liposome-based siRNA therapeutic, 
siRNA-EphA2-DOPC, is currently ongoing to determine the maximum tolerated dose and 
efficacy of EphA2 gene silencing [20]. In addition, the company Dicerna has launched Phase II 
trials with DCR-MYC, a Dicer substrate–based RNAi therapeutic targeting the MYC oncogene 
in solid tumors (especially HCC), multiple myeloma and lymphoma [20].  
 
One implicated oncological target gene is eglin 5 (EG5, also known as Kif11, KSP), a member of 
the Kinesin-5 subclass of kinesins, which is involved in the assembly and organization of the 
mitotic spindle apparatus, and is responsible for centrosome separation in cell division [24]. Thus, 
targeting siRNA against EG5 (siEG5) that corresponds to a sequence of the EG5 coding region 
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conserved between human and mouse, would represent an excellent strategy to hinder mitosis, 
leading to G2 arrest and eventually cell death of cancer cells [25-27]. However, early in vivo 
studies with siRNA described nuclease sensitivity and undesirable immunostimulatory effects 
[28]. For this, Judge et al. used 2' OMe-modified siRNA to prevent the recognition by the innate 
immune system [29, 30]. 
 
Table 1.2.1. RNAi-based drugs in clinical trials.a 
Drug Target  Delivery system Disease Phase Company NCT No. 
TKM-080301 PLK1 LNP HCC I/II Arbutus NCT01262235 
siG12D LODER KRAS-G12D Polymer (local administration) Pancreatic cancer I Silenseed NCT01188785 NCT01676259 
siRNA–EphA2– 
DOPC 
EphA2 LNP Advanced cancers I MD Anderson NCT01591356 
DCR-MYC MYC LNP Solid tumors, Multiple myeloma, Lymphoma 
I I/II Dicerna NCT02110563 NCT02314052 
ALN–VSP02 KSP & VEGF LNP Solid tumors I Alnylam NCT01158079 
Atu027 PKN3 LNP Pancreatic cancer II Silence Therapeutics NCT01808638 
aAbbreviations: LNP, lipid nanoparticle; HCC, hepatocellular carcinoma; PLK1, polo-like kinase 1; LODER, local 
drug eluter; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; EphA2, ephrin type-A receptor 2; KRAS-G12D, 
Kirsten rat sarcoma viral oncogene homolog G12D mutation. The information for clinical trials are published by U.S. 
National Institutes of Health [20]. 
 
1.3 Sequence-defined oligomers for siRNA delivery 
The main hurdles against efficient cytosolic siRNA delivery include: (i) high charge distribution 
and size of siRNA impede its translocation through the cell membrane [31]; (ii) siRNA is 
biologically fragile and is actively targeted by nucleases for degradation in extracellular and 
intracellular environments [32]; (iii) upon systemic administration, negative charge of siRNA may 
be recognized by pattern recognition receptors (PRRs) triggering the innate immune response [5]; 
and naked siRNA is subject to rapid elimination by renal clearance [33]. It is generally realized 
that transforming siRNA from valuable research tool to clinical application is highly dependent 
on the development of safe and efficient delivery systems. 
 
siRNA carriers have recently shown great potential for low toxicity and effective delivery to target 
cells/tissues [31, 34]. Recently, our laboratory, has developed a solid phase supported synthesis 
method [35], where oligoamidoamine building blocks (as proton sponge motifs) were applied 
together with lysines (as branching units), various fatty acids (as stabilizing hydrophobic domains), 
and cysteines (as bioreversible disulfide-forming units) to generate sequence-defined 
monodisperse peptide-like oligomers [26, 36, 37]. 
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It is widely recognized that different non-viral vectors utilize different endocytic pathways in 
order to gain access to the cells [38]. Consequently, both vectors and their respective cargo remain 
to high extent entrapped in endosomal compartments and this endosomal entrapment serves as the 
main limiting factors in their efficient delivery. Many different strategies have been investigated 
aiming to induce endosomal escape [39]. Above-mentioned oligoamidoamine-based building 
blocks such as succinoyl-tetraethylene pentamine (Stp) and succinoyl-pentaethylene hexamine 
(Sph) [40] are designed in the way that they would act as proton sponge motifs, which express 
about 20% protonation of nitrogens at neutral pH and would become increasingly protonated with 
endolysosomal acidification. The influx of protons is followed by subsequent rupture of the 
endosomal membrane and release of the polyplexes [36, 39]. 
 
It is believed that polyplex formation between the cationic carriers and nucleic acids, i.e. siRNA, 
takes place due to the electrostatic interaction between the nitrogens of the oligomers and the 
phosphates of the siRNA [41]. In addition to electrostatic interaction, hydrogen bonding and 
hydrophobic interactions can increase polyplexes stability [39]. For example, lipid moieties can 
be incorporated to increase hydrophobicity, improve polyplex stability and also introduce pH-
dependent lytic activity, leading to enhanced membrane destabilization with endosomal 
acidification [35, 36]. Moreover, the introduction of cysteines that allows disulfide crosslinking 
has been shown to increase particle stability during polyplex formation [36, 42]. In this case, it 
has been hypothesized that siRNA might help bringing the positively charged oligomer molecules 
together into close distance by charge neutralization, followed by disulfide formation to fix the 
nanostructure. Disulfide bonds are stable in the bloodstream but cleaved in the reducing 
environment of the cytosol [39], facilitating dissociation of the particle and release of the siRNA. 
Furthermore, these oligomers could be synthesized with very diverse molecular topologies such 
as i-shape, T-shape, U-shape or branched configurations. Promising candidates of the library such 
as oligomers 49, 229, 278, 386 and 454 (Figure 1.3.1) have shown high activity for siRNA 
delivery, enabling successful silencing of target genes of interest in both in vitro and in vivo 
settings [35-37]. The addition of tyrosines to the terminal cysteines of 454 has rendered the carrier 
even more potent in terms of gene silencing efficiency [37]. From in vivo perspective, the three-
arm oligomer 386 has displayed the fastest onset of protein knockdown and highest in vivo 
antitumoral effect [26]. These oligoamidoamine-based oligomers are also flexible for further 
functional modifications, as targeting and shielding moieties have been successfully incorporated 
into such oligomers [33]. 
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Figure 1.3.1. The structures of oligomers 49, 229, 278, 386 and 454. Apart from 386, these oligomers are modified 
with lipid moieties and contain terminal cysteines, which form intermolecular disulfide bonds after siRNA polyplex 
formation. The oligotyrosines are added to the terminal cysteines of oligomer 454 as stabilizing components for 
siRNA polyplex formation. 
 
1.3.1 Oligoglutamyl-methotrexate (MTX) as bifunctional targeting ligand 
To improve the tissue selectivity and cellular uptake, i.e. to achieve targeted delivery, cationic 
oligomers could be modified with targeting motifs such as antibodies, antibody fragments, small 
molecules, and peptides [33, 43]. As previously reported, oligomer 356 (Figure 1.3.2) contains a 
electrostatic nucleic acid binding core consisted of a branched two-arm structure comprising eight 
Stp units providing the positive charge for siRNA binding, and two cysteines for disulfide-based 
polyplex stabilization [33]. Polyethylene glycol (PEG) comprising 24 ethylene oxide units are 
positioned in the center of the cationic two-arm cores for shielding of the positive surface charge 
and preventing unspecific protein bindings. Moreover, the folate is attached to the exposed part 
of the PEG segment, as targeting ligand for FR-overexpressing tumors. As a result, this folate-
conjugated PEGylated oligomer can formulate siRNA as neutrally-charged monomolecular 
nanoplexes with hydrodynamic diameter of ~6 nm, successfully exhibiting FR-specific cellular 
uptake and gene silencing in vitro and in vivo. 
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Figure 1.3.2. The structure of folate-conjugated PEGylated oligomer 356. 
 
 An interesting strategy is to use a ligand that would be multifunctional, for example combining 
targeting capacity with chemotherapeutic activity. One molecule that could act in this manner is 
the widely used antifolate drug, methotrexate (MTX). MTX and folate (Figure 1.3.3) enter cells 
via two major transport systems: folate receptors (FR) and reduced folate carrier (RFC) [44]. The 
folate receptors consist of several isoforms. FR-α alone is expressed in normal epithelial cells and 
is frequently overexpressed in numerous carcinomas [45]; while RFC is ubiquitously distributed 
[46]. A broad variety of FR-targeted experimental therapies have focused on FR-α, which has thus 
served as a golden standard for targeted drug delivery [47]. Mostly, transport of low molecular 
weight (LMW) MTX occurs via the RFC (Km~1–5 μM); however, LMW MTX also binds to the 
FR-α in the cells with FR-α upregulation [48]. After entering cells, glutamic acid residues are 
attached to MTX by the folylpolyglutamyl synthetase (FPGS), producing MTX polyglutamates 
which are retained in the cytosol and represent the more pharmacologically active form [49]. 
Polyglutamylated MTX inhibits dihydrofolate reductase (DHFR), resulting in inhibition of de 
novo thymidylate and purine synthesis, and consequently DNA and RNA synthesis [46]. Previous 
studies from our lab involving modification of polyglutamylation in covalent MTX-PEG-STP 
conjugates (638-641, see Figure 1.3.4) gave critical evidence that the glutamylation degree is 
closely related to DHFR inhibition potency, cytotoxicity, and cellular uptake [50]. In that work, a 
library of targeted PEGylated oligomers with bifunctional MTX ligands, in order to mediate FR-
specific cellular delivery and augmented tumor suppression was designed and synthesized. 
 
Figure 1.3.3. The structures of folate and methotrexate (MTX). The structural differences between two compounds 
are highlighted in green. 
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Figure 1.3.4. The structures of MTX-conjugated PEGylated oligomer 638-641. 
 
 
1.3.2 Combinatorial optimization of oligomers by covalent coupling 
Successful applications of RNAi-based cancer therapy require sufficient intracellular delivery of 
siRNA to the site of action and effective knockdown of targeted transcripts. Thus, an ideal siRNA 
delivery system should possess multifunctionalities to conquer multiple barriers all the way to its 
target site [31]. Generally, the siRNA carrier needs to incorporate siRNA into nanoparticles of 
suitable size to protect siRNA from nucleases and renal clearance, and also enables passive 
targeting to tumor by enhanced permeability and retention (EPR) effect [51]. 
 
Combination of two different oligomers by covalent coupling provides an efficient alternative to 
obtain a multifunctional carrier, which may formulate therapeutic nucleic acids and overcome 
possible disadvantages of single oligomers. For example, a c-Met targeting PEGylated oligomer, 
which is deficient in DNA condensation, was combined in a 7/3 ratio with a 3-arm oligomer to 
facilitate nucleic acid compaction, and such compaction was critically required for efficient 
intravenous gene delivery, and resulted in greatly enhanced ligand-dependent gene expression in 
the distant tumor [52]. 
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1.3.3 siRNA lipopolyplexes 
As explained above, oligomer 356 (Figure 1.3.2.) successfully exhibited FR-specific cellular 
uptake and gene silencing in vitro and in vivo [33] . However, some limitations remained to be 
overcome. First, because of small particle size, 356 siRNA nanoplexes displayed a short 
circulation time of 15 min followed by renal excretion after systemic administration. Second, 
since 356 siRNA nanoplexes lack robust endosomal escape capacity, modification of siRNA with 
an endosomolytic Inf7 peptide is necessary for potent gene suppression [33, 53]. For systemic 
siRNA administration, an established strategy is to formulate various combinations of lipids and 
polycations to generate lipopolyplexes [54-56]. Hitherto, sorts of cationic polymers were utilized 
in lipopolyplexes such as branched polyethylenimine (bPEI), linear polyethylenimine (lPEI), 
poly-L-lysine (PLL), poly (beta-amino ester), protamine, chitosan, polyallylamine (PAA) and 
other constructs [57-59]. Low molecular weight polyethylenimine (PEI F25-LMW) and various 
lipid combinations are formulated as optimized lipopolyplexes for siRNA delivery [55]. Addition 
of negatively charged and rigid liposomes to pre-condensed polyplexes decreased intrinsic 
cytotoxicity of PEI [55]. Moreover, combination of PEI (2 kDa) and various cationic liposomes 
with or without transferrin was developed by Penacho et al. [60]. Among these transferrin-
modified formulations lipopolyplexes composed of DOTAP/Chol showed the upmost transfection 
efficiency [60]. These results showed that the combination of the polyplexes with fatty acids 
renders DNA/siRNA carriers desirable physicochemical and pharmacological characteristics for 
a more efficient cargo delivery. 
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1.4 Aim of the thesis 
Potent sequence-selective gene silencing by siRNA therapeutics is promising in cancer treatment, 
and the goal of this thesis was to optimize nanosized siRNA delivery system for in vivo application 
evaluated using antitumoral siRNA in the FR-overexpressing tumor models. Through various 
experiments we expected to achieve the following aims:  
 
(i) The first aim was to evaluate a library of PEGylated Stp oligomers with bifunctional MTX 
ligands for siRNA delivery. It had to be investigated whether these siRNA polyplexes can access 
tumor cells specifically through the FR, and to be evaluated if Inf7-modified siEG5 (siEG5-Inf7) 
can be formulated with MTX-linked oligomers to mediate tumor cell-specific cytotoxicity in vitro. 
It also had to be examined if the transfection efficiency was elevated with an increasing degree of 
polyglutamylation of MTX-conjugated oligomers. Eventually, intratumoral treatment in KB 
tumor-bearing mice had to be performed, in order to find out whether these siRNA polyplexes can 
prolong tumoral retention time and enhance antitumoral effect via dual mechanisms. 
 
(ii) Since systemic delivery of siRNA directed to the tumor site remains a major limitation, this 
thesis (together with the thesis of my colleague Dr. Dongsheng He) also aimed to optimize the 
physicochemical properties of polyplexes by combinatorial optimization of PEGylated folate-
conjugated oligomer and 3-arm oligomer to generate targeted combinatorial polyplexes (TCPs). 
For uni-directional fast coupling between the two groups of oligomers, the cysteine thiol groups 
of one of the oligomers ought to be activated with 5,5’-dithio-bis(2-nitrobenzoic acid) to achieve 
a fast chemical linkage through disulfide formation with the free thiol groups of the other oligomer. 
The particle size, surface charge and siRNA binding activity of TCPs had to be assessed. By 
immuno-TEM in collaboration with Prof. Margus Pooga’s lab (Institute of Molecular and Cell 
Biology, University of Tartu), we sought to confirm the involvement of FR in the cellular uptake 
of TCPs, and to gain more detailed insight into how these polyplexes associate with receptors and 
how they are endocytosed by cells. Finally, by i.v. administration of such formulation in L1210 
tumor-bearing mice, we had to examine if siEG5-Inf7 TCPs were able to induce siRNA delivery 
and subsequent gene silencing in the tumors. 
 
(iii) Next, siRNA polyplexes had to be optimized by co-formulating with a PEGylated folate-
conjugated oligoaminoamide and one of several lipo-oligoaminoamides to develop targeted 
lipopolyplexes (TLPs), in which terminal cysteines of carriers stabilized TLPs by disulfide cross-
linkage. This strategy was applied to render TLPs tunable sizes, surface shielding and improved 
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siRNA binding. In collaboration with Prof. Kazunori Kataoka's lab (Innovation Center of 
NanoMedicine and University of Tokyo), time-lapse confocal microscopy was used to investigate 
the colocalization of TLPs with endosomes and lysosomes and the onset of siRNA release from 
late endosomes. In addition, double-labeled siRNA had to be applied to analyze intracellular 
stability by FRET analysis. As to be tested by systemic administration in L1210 tumor-bearing 
mice, TLPs were anticipated to improve pharmacokinetic profile and mediate tumoral gene 
silencing efficiency with siEG5. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Inf7 peptide (GLFEAIEGFIENGWEGMIDGWYGC-amide) was obtained from Biosyntan 
(Berlin, Germany). 2-Chlorotrityl chloride resin, all Fmoc or Boc protected α-amino acids, peptide 
grade dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), N,N-diisopropylethylamine 
(DIPEA), piperidine and trifluoroacetic acid (TFA) were purchased from Iris Biotech 
(Marktredwitz, Germany). Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate (PyBOP) and syringe microreactors were obtained from Multisyntech 
GmbH (Witten, Germany). Folate, methotrexate, 1-hydroxy-benzotriazole (HOBt), 
triisopropylsilane (TIS), tris(2-carboxyethyl)phosphine (TCEP), 5,5’-dithio-bis(2-nitrobenzoic 
acid) (DTNB), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 3,6-dioxa-1,8-octanedithiol (DODT), 
dimethylsulfoxide (DMSO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) were purchased from Sigma-Aldrich (Munich, Germany); hydrazine hydrate solution from 
Merck (Darmstadt, Germany), and 25% ammonia solution from Carl Roth (Karlsruhe, Germany). 
N10-(trifluoroacetyl) pteroic acid was obtained from Niels Clauson-Kaas A/S (Farum, Denmark), 
and Fmoc-N-amido-dPEG24-acid from Quanta Biodesign (Plain City, OH, USA). Fetal bovine 
serum (FBS) was purchased from Invitrogen (Karlsruhe, Germany), glucose from Merck 
(Darmstadt, Germany), and HEPES from Biomol GmbH (Hamburg, Germany). All other solvents 
were purchased from Sigma-Aldrich (Steinheim, Germany), Iris Biotech (Marktredwitz, 
Germany), Merck (Darmstadt, Germany), Bernd Kraft (Duisburg, Germany) or AppliChem 
(Darmstadt, Germany). 
 
2.1.2 siRNA duplexes 
For flow cytometry, Cy5-labeled siAHA1 was used:  
sense: 5′-(Cy5)(NHC6)-GGAuGAAGuGGAGAuuAGudTsdT-3′; antisense: 5′-
ACuAAUCUCcACUUcAUCCdTsdT-3′ (Axolabs GmbH, Kulmbach, Germany).  
 
For immuno-TEM, biotinylated siRNA was used:  
sense: 5'-(biotinP)GAAAUCGCUGAUUUGUGUAdTdT-3'; antisense: 5'-
UACACAAAUCAGCGAUUUCdTdT-3′ (P: phosphodiester) (Axolabs GmbH, Kulmbach, 
Germany).  
 12 
 
Materials and Methods 
For CLSM, Alexa Fluor (AF) 647-labeled siRNA was applied: 
sense: 5'-AF 647-NH2C6-CUUACGCUGAGUACUUCGAdTdT-3'; antisense: 5'-UCGAAG 
UACUCAGCGUAAGdTdT-3' (Gene Design, Ibaraki, Japan).  
 
For gene silencing studies, siRNA sequences were modified with Inf7 peptide: siGFP-Inf7 
(sense: Inf7-ss-C6-5′-AuAucAuGGccGAcAAGcAdTsdT-3′; antisense: 5′-UGCUUGUCGGC 
cAUGAuAUdTsdT-3′), siEG5-Inf7 (sense: Inf7-ss-C6-5′-ucGAGAAucuAAAcu AAcudTsdT-3′; 
antisense: 5′-AGUuAGUUuAGAUUCUCGAdTsdT-3′) and control sequence siCtrl-Inf7 (sense: 
Inf7-ss-C6-5′-AuGuAuuGGccuGuAuuAGdTsdT-3′; antisense: 5′-CuAAuAcAGGCcAAuAcA 
UdTsdT-3′). Unmodified siRNA sequences were exploited as comparison: siGFP (sense: 5'-
AuAucAuGGccGAcAAGcAdTsdT-3'; antisense: 5'-UGCUUGUCGGCcAUGAuAUdTsdT-3')  
and siCtrl (sense: 5'-AuGuAuuGGccuGuAuuAGdTsdT-3'; antisense 5'-CuAAuAcAGGCcAAu 
AcAU dTsdT-3'); (Axolabs GmbH, Kulmbach, Germany).  
 
For FRET study, Cy5/TAMRA double labeled siRNA was used (sense: 5'-Cy5-NH2C6-CUU 
ACGCUGAGUACUUCGAdTdT-NH2C6-TAMRA-3'; antisense: 5'-UCGAAGUACUCA 
GCGUAAGdTdT-3'); (Hokkaido System Science, Sapporo, Japan).  
 
To evaluate in vivo biodistribution, we used Cy7-labeled siAHA1 (sense: C6-ss-C6-5′- GGAuGA 
AGuGGAGAuuAGudTsdT-3′; antisense: 5′-(Cy7)(NHC6)ACuAAUCUCcACUUcAUCCdT 
sdT-3′); (Axolabs GmbH, Kulmbach, Germany) .  
small letters: 2′-methoxy-RNA; s: phosphorothioate 
 
2.1.3 Oligomers 
Oligomers A-PEG24-K(Stp4-C)2 (188), K(PEG24-MTX)-K(Stp4-C)2 (638), K(PEG24-E2-MTX)-
K(Stp4-C)2 (639), K(dPEG24-E4-MTX)-K(Stp4-C)2 (640), K(PEG24-E6-MTX)-K(Stp4-C)2 (641) 
and K(PEG24-αMTX)-K(Stp4-C)2 (642) were provided by Dr. Ulrich Lächelt [50, 53], C-Stp4-
K(Stp4-C)-dPEG24-Folate (356) was provided by Dr. Dongsheng He and Philipp Klein [33], C-
Stp3-K-(Stp3-C)2 (386), C-H-(Stp-H)3-K-[(H-Stp)3-H-C]2 (689), K-(PEG24-Folate)-K-[K-(Sph4-
C)2]2 (709), K-(PEG24-Folate)-K-(Sph4-Y3-C)2 (717), TNB-C-Stp3-K-(Stp3-C-TNB)2 (769), 
TNB-C-H-(Stp-H)3-K-[(H-Stp)3-H-C-TNB]2 (770), K-(PEG24-Folate)-K-[K-(Sph4-C-TNB)2]2 
(873) and K-(PEG24-Folate)-K-(Sph4-Y3-C-TNB)2 (874) were provided by Dr. Dongsheng, C-Y3-
Stp2-[(OleA)2-K]K-Stp2-Y3-C (454), C-Stp2-[(OleA)2-K]K-Stp2-C (49) and (LinA)2-K-C-Stp3-C 
(229) were provided by Dr. Dongsheng and Sören Reinhard [36, 37].   
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2.2 Methods 
2.2.1 siRNA polyplex formation 
The amount of oligomer (noligomer, nmole) for the fixed amount of nucleic acid is calculated via 
N/P (pronatable amines of the oligomer/phosphates of the siRNA) ratio: 
𝑛𝑛oligomer(𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛) = msiRNA(ng)MsiRNA ∙ PsiRNA ∙ N/PNoligomer 
msiRNA: weight of siRNA (ng); MsiRNA: molecular weight of siRNA; PsiRNA: amount of phosphates 
of siRNA; Noligomer: amount of pronatable amines of oligomer. 
 
Polyplexes for transfections were prepared (unless otherwise mentioned) as follows: 500 ng of 
siRNA and the calculated amount of oligomer at the indicated N/P ratios were separately diluted 
in 10 μL of 20 mM HEPES buffered 5% glucose pH 7.4 (HBG). The oligomer solution was added 
to the nucleic acid solution and mixed by rapid pipetting (at least 5 times) to obtain totally 20 μL 
of polyplex solution. The polyplexes were allowed to form for 40 min under exposure to air 
oxidation at room temperature in the closed Eppendorf tube. 
 
2.2.2 Formulation of targeted combinatorial polyplexes (TCPs) 
Calculations of the individual two oligomers used at N/P 16 in formation of TCPs at indicated 
molar ratios were made as follows.  
• Protonatable nitrogens (N) for the applied oligomers in the current work were calculated 
excluding histidine Ns (defined as unprotonated at pH 7.4): N = 29 for 386/769, N = 29 
for 689/770, N = 68 for 709/873, N = 34 for 717/874. 
• The required molar amine amounts of oligomers at N/P 16 were calculated, which are 
24.88 nmol nitrogens (N) for 500 ng of siRNA (in transfection). For size measurements 
10 µg of siRNA were used, corresponding to 498 nmol N. 
• For the following calculation of the molar amount of each oligomer, general formulas were 
applied as follows: 
1) N/Ptotal = 16 = N/Pa + N/Pb ("a" and "b" to stand for the two oligomers). 
2) Total molar amount of nitrogen Mtotal = Na × Ma + Nb × Mb, here N stands for the number 
of protonatable nitrogens, while M stands for the molar amount. 
3) The molar ratio of oligomers Ma/Mb = Ra/Rb.    
R stands for the ratio of each oligomer (1:1 in the majority of cases). 
4) Calculation of the molar amount of each oligomer:  
 14 
 
Materials and Methods 
Ma = 16 × Mtotal × Na/(Na + Nb × Rb/Ra), and Mb = 16 × Mtotal × Nb/(Na × Ra/Rb + Nb). 
5) The individual N/P ratio for each oligomer (at N/Ptotal = 16): 
N/Pa = 16 × Na/(Na + Nb × Rb/Ra), and N/Pb = 16 × Nb/(Na × Ra/Rb + Nb). 
• As an example of TCP1 386/873 at molar ratio 40:60, the individual N/P for 386 is 16 × 
29/(29 + 68 × 60/40) = 3.5, for 873 it is 16 × 68/(29 × 40/60 + 68) = 12.5, and the molar 
amount M for 386 is 24.88 × 29/(29 + 68 × 60/40) = 5.45 nmol for 500 ng of siRNA. 
Please note that, depending on the selected molar ratios and TCPs, the final molar ratios of thiol 
SH / TNB will differ. At oligomer molar ratio of 1:1, SH / TNB is 3:4 for TCP1, 2:3 for TCP2, 
4:3 for TCP3, and 3:2 for TCP4.  
 
siRNA polyplexes were prepared (unless otherwise mentioned) as follows: at the indicated N/P 
ratios, 500 ng of siRNA was diluted in 10 μL of HBG, and the calculated amount of the two 
oligomers for the designated [TNB-modified oligomer / unmodified mercapto-form of oligomer] 
molar ratio, were separately diluted in 5 μL of HBG. The solution of the first TNB-modified 
oligomer was added to the siRNA solution and mixed by rapid pipetting (at least 5 times) to obtain 
15 μL of binary siRNA polyplex solution. After 30 min in the closed Eppendorf reaction tube at 
room temperature, the solution of the second oligomer was added to the siRNA polyplex solution, 
to obtain 20 μL of siRNA polyplex solution in total. The solution was placed for further 40 min 
at room temperature for disulfide formation. 
 
2.2.3 Formulation of targeted lipopolyplexes (TLPs) 
The individual two oligomers at N/P 16 in preparation of TLPs at indicated molar ratios were 
calculated as follows:  
• Protonatable nitrogens (N) for the applied oligomers: N = 25 for 356, N = 13 for 49, N = 
9 for 229, N = 13 for 454. 
• The required molar amine amounts of oligomers at N/P 16 were calculated, which are 
24.88 nmol nitrogens (N) for 500 ng of siRNA. 
• For the following calculation of the molar amount of each oligomer, general formulas were 
applied as follows: 
1) N/Ptotal = 16 = N/Pa + N/Pb ("a" and "b" to stand for the two oligomers). 
2) Total molar amount of nitrogen Mtotal = Na × Ma + Nb × Mb, here N stands for the number 
of protonatable nitrogens, while M stands for the molar amount. 
3) The molar ratio of oligomers Ma/Mb = Ra/Rb 
R stands for the ratio of each oligomer (e.g. 356:454 = 30%:70% for TLP1 and 356:49 = 
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30%:70% for TLP2). 
4) Calculation of the molar amount of each oligomer:  
Ma = 16 × Mtotal × Na/(Na + Nb × Rb/Ra), and Mb = 16 × Mtotal × Nb/(Na × Ra/Rb + Nb). 
5) The individual N/P ratio for each oligomer (at N/Ptotal = 16): 
N/Pa = 16 × Na/(Na + Nb × Rb/Ra), and N/Pb = 16 × Nb/(Na × Ra/Rb + Nb). 
• As an example of TLP1 containing 356:454 at molar ratio of 30%:70%, the individual N/P 
for 356 is 16 × 25/(25 + 13 × 70/30) = 7.2, for 454 it is 16 × 13/(25 × 30/70 + 13) = 8.8, 
and the molar amount M for 356 is 24.88 × 25/(25 + 13 × 70/30) = 11.25 nmol for 500 ng 
siRNA. 
 
siRNA polyplexes were prepared (unless otherwise mentioned) as follows: at the indicated N/P 
ratios, 500 ng of siRNA was diluted in 10 μL of HBG, and the calculated amount of the two 
oligomers for the designated [targeted PEG oligomer / lipo-oligomer] molar ratio at N/P 16 were 
diluted in 10 μL of HBG. The oligomer solution was added to the nucleic acid solution and mixed 
by rapid pipetting (at least 5 times) to obtain totally 20 μL of polyplex solution. The polyplexes 
were allowed to form for 40 min under exposure to air oxidation at room temperature in the closed 
Eppendorf tube. 
 
2.2.4 Fluorescence correlation spectroscopy (FCS) 
To estimate the hydrodynamic radii of the polyplexes, fluorescence correlation spectroscopy (FCS) 
was used. Unlabeled control siRNA (siCtrl) was spiked with 20% of Cy5-labeled siRNA in HBG. 
Polyplexes containing 10 μg of siRNA for the indicated N/P ratio were prepared in 50 μL of HBG. 
After incubation at room temperature for 40 min to form polyplexes, the samples were diluted 
1:40 in HEPES (20 mM, pH 7.4) and were measured on a home-built confocal microscope by 
excitation of Cy5 with a pulsed 640 nm laser (LDH-D-C-640, Picoquant, Berlin, Germany). The 
FCS volume was calibrated using fluorophores with known diffusion coefficients with the 
calculated probe volume, where the diffusion coefficients could be directly determined by fitting 
the autocorrelation function. Hydrodynamic radii were calculated from the diffusion coefficients 
using the Stokes-Einstein relationship assuming a spherical shape of the particles. A detailed 
description of the method could be found in the supplementary materials in [53]. 
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2.2.5 Size and zeta potential by dynamic light scattering (DLS) measurements 
Particle sizes and zeta potentials of siRNA polyplexes were measured using Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, U.K.). siRNA polyplexes containing 1.5 μg of nucleic acid 
in a total volume of 60 μL were further diluted 1:20 with HEPES buffer (20 mM, pH 7.4) before 
measuring in a folded capillary cell (DTS1060 or DTS1070). For size measurements, each sample 
was measured three times with 10 subruns at 25 °C. Zeta potential was calculated by the 
Smoluchowski equation, and each sample was measured 3 times with 10 to 30 subruns at 25 °C. 
 
2.2.6 Gel shift assay 
A 2.5% (w/v) agarose gel was prepared by dissolving agarose in TBE buffer (10.8 g of Trizma 
base, 5.5 g of boric acid, 0.75 g of disodium EDTA, and 1 L of water). After adding GelRed 
(Biotium, Hayward, CA, USA), the agarose gel was formed in the electrophoresis chamber. 
siRNA polyplexes containing 500 ng of siRNA were formed and loaded into the wells in the gel 
after adding 4 μL of loading buffer (6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 
0.02 g of bromophenol blue). Electrophoresis was performed at 120 V for 40 min and the results 
were recorded by UV transilluminator (Dark Hood DH-40, Biostep, Burkhardtsdorf, Germany). 
 
2.2.7 Particle imaging by transmission electron microscopy (TEM) 
A formvar-carbon 300 mesh copper grid (Ted Pella, Redding, CA, USA) was activated by mild 
plasma cleaning. Afterwards, one drop (10 µL) of the siRNA polyplex solution at N/P 16 (diluted 
in water) was placed on the grid. Excess liquid was blotted off using filter paper until the grid was 
almost dry. Subsequently, the copper grid was stained with 10 μL of 1% phosphotungstic acid 
(PTA) solution (Sigma-Aldrich, Munich, Germany), and analyzed using JEM 1011 transmission 
electron microscope (JEOL, Tokyo, Japan) at 80 kV. 
 
2.2.8 Atomic force microscopy (AFM) 
Polyplexes containing 10 μg of siRNA and the according amount of oligomer for N/P 16 were 
prepared in 50 μL of HBG. Samples were incubated for 40 min to ensure complete polyplex 
formation. Samples were diluted 1:50 for AFM measurements in HEPES (20 mM, pH 7.4). The 
glass slides (diameter of 30 mm, Assistent, Sondheim, Germany) were used as negatively charged 
flat substrates for particles to be attached onto. After polyplex formation, 500 μL of the diluted 
polyplexes with positive surface charge were deposited onto the glass slide, which was mounted 
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to a sample plate (Agilent Technologies, Santa Clara, CA, USA) and incubated for ∼3 min, 
resulting in a surface coated with particles. The solution on the glass slide was subsequently 
replaced by the pure HEPES (20 mM, pH 7.4). After mounting the sample plate onto the AFM, 
the cantilever was installed into the device. Samples were imaged with the contact mode on AFM 
(AFM6000, Agilent Technologies, Santa Clara, CA, USA). Imaging at room temperature was 
performed with silicon nitride cantilevers (MSCT, nominal spring constant of 10 pN/nm, Bruker, 
Billerica, MA, USA). Imaging parameters were optimized for best image quality, in combination 
with the maintenance of the lowest possible set point to minimize damage to the samples.  
 
2.2.9 Cell culture 
As FR-expressing cell lines, murine lymphocytic leukemia cells (L1210), murine lung carcinoma 
cells (M109), human cervix carcinoma cells (KB), and human cervix carcinoma cells stably 
transfected with the eGFPLuc (enhanced green fluorescent protein/luciferase) gene (KB/eGFPLuc) 
were cultured in folate-free RPMI 1640 medium (Invitrogen, Karlsruhe, Germany), supplemented 
with 10% fetal bovine serum (FBS), 4 mM stable glutamine, 100 U/mL penicillin, and 100 μg/mL 
streptomycin. Human alveolar adenocarcinoma cells (A549), human mammary adenocarcinoma 
cells (MCF-7), and human mammary adenocarcinoma cells expressing eGFPLuc gene (MCF-
7/eGFPLuc) were used as FR-deficient controls. A549 cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 10% fetal calf serum, 4 mM stable 
glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. MCF-7 and MCF-7/eGFPLuc cells 
were grown in DMEM, supplemented with 20 % FBS, 4 mM stable glutamine, 100 U/mL 
penicillin, and 100 μg/mL streptomycin. The cells were cultured in ventilated flasks inside 
incubators at 37°C with 5% CO2 in a humidified atmosphere. Cell lines were grown to 80 - 90% 
confluent and harvested. 
 
2.2.10 Cellular association and internalization study 
For flow cytometric measurements, unlabeled control siRNA (siCtrl) was spiked with 20% of 
Cy5-labeled siRNA (Cy5-siAHA1) in HBG. L1210 cells were seeded onto 24-well plates at a 
density of 2 × 105 cells/well in 450 µL of fresh growth medium. KB, M109, A549 and MCF-7 
cells were seeded onto 24-well plates at a density of 5 × 104 cells/well, and 24 h later the medium 
was replaced by 450 µL of fresh growth medium. The cells were treated with 50 µL of siRNA 
polyplexes containing 2.5 µg of siRNA and corresponding amount of oligomer at N/P 16 (final 
siRNA concentration: 370 nM). The 24-well plates were incubated on ice for 45 min for cellular 
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association, or at 37 °C for 4 h for cellular internalization. Then the samples were prepared for 
flow cytometric measurements. 
 
2.2.11 Ligand competition study 
KB cells were seeded onto 24-well plates at a density of 5 × 104 cells/well, and 24 h later the 
medium was replaced with 450 µL of fresh growth medium, or 450 µL of fresh growth medium 
containing 100 µM MTX or 100 µM folate, and cells were incubated at 37 °C for 30 min. Then 
50 µL of polyplexes containing 2.5 µg of siRNA and indicated amount of oligomer at N/P ratio 
of 16 (final siRNA concentration: 370 nM) were applied onto the cells. The cells were placed in 
the incubator at 37 °C for 4 h before flow cytometric measurement. 
 
2.2.12 Fluorescence resonance energy transfer (FRET) intensity in Cy5/TAMRA double-
labeled siRNA 
KB or L1210 cells were seeded onto 12-well plates at a density of 5 × 104 cells/well, and 24 h 
later the medium was replaced with 900 µL of fresh growth medium. The cells were treated with 
100 µL of polyplexes containing 5 µg of Cy5/TAMRA double-labeled siRNA at N/P 16 (final 
siRNA concentration: 370 nM) for 45 min. The cells were placed in the incubator at 37 °C for 2 
and 4 h before flow cytometric measurement. 
 
2.2.13 Flow cytometry 
After transfection, the medium was removed and cells were washed twice with PBS. KB, M109 
and MCF-7 cells were trypsinized, and then trypsin was inactivated with 1000 µL of FACS buffer 
(10% FBS in PBS). The cells were centrifuged (1000 rpm; 5 min) and then resuspended in 600 
µL of FACS buffer. For cellular internalization study, the samples were immediately mixed with 
DAPI at a final concentration of 1 ng/μL before flow cytometry. The amount of Cy5-positive cells 
was counted through excitation of Cy5 at 635 nm and detection of emission at 665/20 nm by Cyan 
ADP flow cytometer (Beckman Coulter, Fullerton, CA, USA). The results were recorded by 
Summit software V4.3.02 (Summit, Jamesville, NY, USA) and evaluated using FlowJo V10.0.6 
software (FlowJo, Ashland, OR, USA). For FRET analysis, fluorescence intensity of the cells was 
measured by BD LSRFortessa X-20 (BD Biosciences, Franklin Lakes, NJ, USA) and evaluated 
using FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA) at excitation wavelength 
of 488 nm and a 660/20 nm filter. All experiments were performed in triplicates. 
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2.2.14 Intracellular distribution of siRNA polyplexes by time-lapse imaging 
5 × 105 KB cells were seeded on 35 mm micro-dishes (ibidi GmbH, Martinsried, Germany) and 
were incubated with CellLight Late Endosomes-RFP and CellLight Lysosomes-GFP (both from 
Molecular Probes, Eugene, OR, USA) overnight before measurements. Unlabeled control siRNA 
(siCtrl) was spiked with 30% of AF 647-labeled siRNA in HBG. Polyplexes containing 5 μg of 
siRNA for N/P 16 were prepared in 100 μL of HBG. The medium was replaced with 900 µL of 
fresh medium and 100 μL of polyplexes containing 5 μg of siRNA at N/P 16 (final siRNA 
concentration: 370 nM). The nuclei were stained with 10 μL/mL of Hoechst 33342 (Dojindo 
Laboratories, Kumamoto, Japan) for 3 min. The intracellular distribution of siRNA was observed 
using time-lapse imaging by CLSM (LSM 880, Carl Zeiss, Oberkochen, Germany) for 16 h with 
a Plan-Apochromate 63×/1.4 oil objective lens, diode laser (405 nm) for Hoechst 33342, Ar laser 
(458 nm/488 nm/514 nm) for CellLight Late Endosomes-GFP, DPSS laser (561 nm) for CellLight 
Late Endosomes-RFP and He−Ne laser (633 nm) for AF 647. ZEN 2.1 software (Carl Zeiss, 
Oberkochen, Germany) was used to process the imaging data. 
 
2.2.15 Endosomal escape of siRNA polyplexes by 3D image reconstruction 
5 × 105 KB cells were seeded on 35 mm micro-dishes (ibidi GmbH, Martinsried, Germany) and 
were incubated with CellLight Late Endosomes-RFP and CellLight Lysosomes-GFP (both from 
Molecular Probes, Eugene, OR, USA) overnight before measurements. Unlabeled control siRNA 
(siCtrl) was spiked with 30% of AF 647-labeled siRNA in HBG. Polyplexes containing 5 μg of 
siRNA for N/P 16 were prepared in 100 μL of HBG. The medium was replaced with 900 µL of 
fresh medium, and 100 μL of polyplex containing 5 μg of siRNA at N/P 16 was added (final 
siRNA concentration: 370 nM). After transfection for 45 min, the intracellular distribution of 
siRNA was observed using 3D reconstruction from serial images from single cell by super-
resolution CLSM (LSM 880 combined, Carl Zeiss, Oberkochen, Germany) at 4 h with the 
abovementioned lens and lasers. 
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2.2.16 Colocalization analysis of siRNA polyplexes and endolysosomal vesicles. 
5 × 104 KB cells were seeded onto 8-well micro-chamber slides (ibidi GmbH, Martinsried, 
Germany). The medium was replaced by 180 μL of fresh medium 24 h later. Unlabeled control 
siRNA (siCtrl) was spiked with 30% of AF 647-labeled siRNA in HBG. Late endosomes and 
lysosomes were labeled with LysoTracker Green (Molecular Probes, Eugene, OR, USA) and the 
cells were transfected with 20 μL of polyplexes (final concentration: 370 nM at N/P 16) for 45 
min. The transfection medium was removed, and then cells were washed with 200 μL of PBS and 
fixed with 4% paraformaldehyde. Nuclei were stained with DAPI. The intracellular distribution 
of siRNA was observed by CLSM (LSM 880, Carl Zeiss, Oberkochen, Germany) at 2 and 4 h 
using a 63×/1.4 oil objective lens, diode laser (405 nm) for DAPI, Ar laser (458 nm/488 nm/514 
nm) for LysoTracker Green and He−Ne laser (633 nm) for AF 647. 
Colocalization ratios of AF 647-labeled siRNA with late endosomes and lysosomes were 
calculated using ZEN 2.1 software as follows: 
colocalization ratio = AF 647 pixelscolocalization /AF 647 pixelstotal 
where AF 647 pixelscolocalization represents the number of AF 647 pixels overlapping with 
LysoTracker Green, and AF 647 pixelstotal represents the total number of AF 647-positive pixels 
in the cell. For each condition, colocalization ratios were calculated from 5 individual cells. 
 
2.2.17 Fluorescence resonance energy transfer (FRET) imaging in Cy5/TAMRA double-
labeled siRNA 
5 × 104 KB cells were seeded onto 8-well micro-chamber slides (ibidi GmbH, Martinsried, 
Germany) and labeled with CellLight Lysosomes-GFP (Molecular Probes, Eugene, OR, USA) 
overnight before measurements. The medium was replaced by 180 μL of fresh medium, and the 
cells were transfected with 20 μL of polyplexes containing Cy5/TAMRA double-labeled siRNA 
(final concentration: 370 nM at N/P 16) for 45 min. The transfection medium was removed, and 
then cells were washed with 200 μL of PBS and fixed with 4% paraformaldehyde. Nuclei were 
stained with DAPI. The FRET signal of siRNA was observed by CLSM (LSM 880, Carl Zeiss, 
Oberkochen, Germany) at 1 and 24 h using a 561nm excitation laser and the lambda stacks were 
obtained within a range of 565 to 700 nm at a bandwidth of 4.5 nm. The spectral images obtained 
were linearly unmixed to Cy5 and TAMRA spectra. 
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2.2.18 Pre-embedding immuno-labeling for TEM 
To visualize the siRNA molecules for immuno-electron microscopy, the biotinylated siRNA (740 
nM) was first associated with 10 nm neutravidin-gold conjugate (at molecular ratio of 3:1) for 10 
min, followed by complexation with the calculated amount of oligomers at N/P 16 in HBG. KB 
cells were seeded onto round glass coverslips (diameter of 12 mm, Menzel Gläser, Braunschweig, 
Germany) in 35 mm petri dishes and grown to 80–90% confluence. Thereafter, the coverslips 
were transferred into wells of 24-well plate and incubated with siRNA polyplexes in culture 
medium for 15 min, 1 h or 4 h at 37 °C. After incubation, the cells were washed and fixed with 
PLP fixative according to McLean and Nagane [61] (2% formaldehyde, 0.01 M sodium periodate, 
0.075 M lysine in 0.075 M sodium phosphate buffer) at room temperature for 2 h. Cells were 
slightly permeabilized with 0.01% saponin (Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 0.1% BSA in 0.1 M sodium phosphate buffer for 8 min. After permeabilization, the cells 
were stained with mouse IgG against FR (R&D Systems, Minneapolis, MN, USA) for 1 h and 
Protein G-6 nm gold conjugate (1:40) (Aurion Immuno Gold Reagents & Accessories, 
Wageningen, Netherlands) for an additional 1 h. Then the cells were washed, postfixed with 1% 
osmium tetroxide in the 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h at room temperature, 
and dehydrated with ethanol. The specimens were embedded in epoxy resin (TAAB Laboratories 
Equipment Ltd., Reading, UK), cut into ultrathin sections, and contrasted with uranyl acetate and 
lead citrate. The sections were examined with Tecnai G2 Spirit BioTWIN transmission electron 
microscope (FEI, Eindhoven, Netherlands) at 120 kV. Electron microphotos were analyzed and 
processed with Photoshop CS6 (Adobe, San Jose, CA, USA). 
 
2.2.19 Gene silencing mediated by GFP-siRNA in vitro 
Cells were seeded in 100 μL of medium using 96-well plates at a density of 4 × 103 cells for 
KB/eGFPLuc and 5 × 103 cells for MCF-7/eGFPLuc per well 24 h prior to the experiment. Before 
the treatment, medium was replaced with 80 μL of fresh growth medium. siGFP and siGFP-Inf7 
were used for silencing of the eGFPLuc protein in comparison with control siRNA (siCtrl and 
siCtrl-Inf7). Cells were transfected with 20 μL of siRNA polyplexes containing 500 ng of siRNA 
at certain N/P ratios (final siRNA concentration: 370 nM) at 37 °C for 45 min, then the medium 
was replaced by 100 μL of fresh growth medium. After incubation for 48 h, the medium was 
removed and 100 μL of cell culture lysis reagent (Promega, Mannheim, Germany) was added per 
well. Luciferase activity was measured using the luciferase assay kit (Promega, Mannheim, 
Germany) and recorded on a Centro LB 960 plate reader luminometer (Berthold, Bad Wildbad, 
Germany). The relative light units (RLU) are presented as percentage of the luciferase gene 
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expression obtained with untreated control cells. 
 
2.2.20 Cytotoxicity mediated by EG5 knockdown or MTX conjugates 
4 × 103 KB or M109 cells per well were seeded into 96-well plates in 100 μL of growth medium 
24 h prior to the treatment. Medium was replaced by 80 μL of fresh medium and 20 μL of 
polyplexes (at N/P 16 with siEG5, siCtrl, siEG5-Inf7, or siCtrl-Inf7; final concentration of siRNA: 
370 nM), plain oligomer, or MTX solution in HBG. After incubation for 24 h (37 °C, 5% CO2), 
medium was replaced by 100 μL of fresh growth medium and the cells were maintained for 24 h 
(37 °C, 5% CO2). MTT assay (Life Technologies, Darmstadt, Germany) for metabolic activity 
was performed to evaluate the cell viability and measured by SpectraFluor Plus microplate reader 
(Tecan, Männedorf, Switzerland). The experiments were performed in triplicates and the cell 
viability was calculated as percentage compared to untreated control cells. 
 
2.2.21 Evaluation of mitotic aster formation 
KB or M109 cells (1 × 104/well) were seeded in 200 μL of fresh growth medium using 8-well 
Lab-Tek chamber slides (Nunc, Penfield, NY, USA). The medium was replaced by 180 μL of 
fresh medium 24 h later. The cells were transfected with 50 μL of polyplexes containing 1.15 µg 
of siRNA (with siEG5, siCtrl, siEG5-Inf7, or siCtrl-Inf7; final concentration: 370 nM at N/P 16) 
and incubated for 48 h (37 °C, 5% CO2). The transfection medium was removed, and then cells 
were washed with 200 μL of PBS and fixed with 4% paraformaldehyde. Nuclei were stained with 
DAPI (1 μg/mL) and observed under Axiovert 200 fluorescence microscope (Carl Zeiss, 
Oberkochen, Germany). 
 
2.2.22 Quantitative real-time polymerase chain reaction (qRT-PCR) 
qRT-PCR was performed to determine the mRNA level of EG5 gene in transfected cells. KB or 
L1210 cells (1.5 ×105/well) were seeded in 900 μL of medium onto 6-well plates. The cells were 
treated with 100 μL of siRNA polyplexes (N/P 16) with a final siRNA concentration of 370 nM 
and incubated for 24 h. Total RNA was isolated by miRCURY RNA Isolation Kit (Exiqon, 
Vedbaek, Denmark) followed by reverse transcription using Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche, Mannheim, Germany) according to the manufacturers’ protocols. qPCR 
was performed in triplicates on a LightCycler 480 system (Roche, Mannheim, Germany) using 
UPL Probes (Roche, Mannheim, Germany) and Probes Master (Roche, Mannheim, Germany) 
with GADPH as housekeeping gene. The following probes and primer sequences were used: 
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human or murine GAPDH (ready-to-use in UPL), human EG5 (UPL Probe #53) (forward: 
CATCCAGGTGGTGGTGAGAT, reverse: TATTGAATGGGCGCTAGCTT), and murine EG5 
(UPL Probe #100) (forward: TTCCCCTGCATCTTTCAATC, reverse: TTCAGGCTTATTCAT 
TATGTTCTTTG). Results were analyzed by the ΔCT method. CT values of GAPDH were 
subtracted from CT values of EG5. ΔCT values of transfected cells were calculated as percentage 
relative to untreated control cells. 
 
2.2.23 Tumor mouse model 
Female 8-week-old nude mice, Rj: NMRI-nu (nu/nu) (Janvier, Le Genest-Saint-Isle, France), 
were housed in isolated ventilated cages under specific pathogen-free condition with a 12 h 
light/dark interval, and were acclimated for at least 7 days prior to experiments. Food and water 
were provided ad libitum. Animals were injected with 5 × 106 KB or 0.5-2 × 106 L1210 cells 
subcutaneously (s.c.) for biodistribution study, and were injected with 5 × 106 KB or 1 × 106 
L1210 cells subcutaneously for EG5 gene silencing assay in vivo. The body weight was recorded, 
and the tumor volume was measured by caliper and calculated as [0.5 × (longest diameter) × 
(shortest diameter)2] as stated by Xu et al. [62]. All animal experiments were performed according 
to guidelines of the German law for the protection of animal life and were approved by the local 
animal ethics committee. 
 
2.2.24 Biodistribution study 
For near infrared (NIR) in vivo imaging, unlabeled control siRNA (siCtrl) was spiked with 50% 
of Cy7-labeled siRNA (Cy7-siAHA1) in HBG. When tumors reached the size of 500–800 mm3, 
the mice (n = 3-4/per group) were anesthetized with 3% isoflurane in oxygen. siRNA polyplexes 
containing 50 µg of Cy7-labeled siRNA (N/P 16) in 50 µL of HBG were injected intratumorally 
(i.t.), or in 250 µL of HBG were injected intravenously (i.v.), and fluorescence was measured with 
a CCD camera. Animals were sacrificed for ex vivo imaging of tumors and organs at different 
time intervals after injection. For evaluation of images, efficiency of fluorescence signals was 
analyzed, after color bar scales were equalized using IVIS Lumina system with Living Image 
software 3.2 (Caliper Life Sciences, Hopkinton, MA, USA). 
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2.2.25 Antitumoral potency mediated by EG5 knockdown and MTX conjugates 
The animals were randomly divided into 6 groups (n = 6), and 2 days after inoculation of tumor 
cells, the animals were injected i.t. with 50 μL of polyplexes containing 50 µg of siRNA at N/P 
16, corresponding amount of plain oligomer or methotrexate. Treatments were applied on day 2, 
4, 7, 10, 14 and 17. Tumor sizes of the animals were monitored. Animals were sacrificed after the 
tumor size reached 1000 mm3, and Kaplan–Maier survival analysis was performed to compare the 
lifetime after treatments among different groups. 
 
2.2.26 Gene silencing mediated by EG5-siRNA in vivo 
When tumors reached 500 mm3, mice (n = 5/per group) were injected i.v. with polyplexes 
containing 50 µg of siRNA (at N/P 16 with siEG5, siCtrl, siEG5-Inf7, or siCtrl-Inf7) 48 and 24 h 
before euthanasia. As a part of terminal procedure, blood samples were obtained by cardiac 
puncture for blood biochemistry examination. After tumors were harvested and homogenized, 
total RNA was extracted using Trifast (Peqlab, Erlangen, Germany) according to the 
manufacturer’s protocol. The reverse transcription and qRT-PCR was performed as 
aforementioned. 
 
2.2.27 Blood biochemistry examinations 
To isolate plasma, blood samples were collected in EDTA-coated tubes (Multivette 600, Sarstedt, 
Nümbrecht, Germany) and centrifuged at 3000 rpm for 7 minutes. The supernatant was analyzed 
for clinical biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), blood urea nitrogen (BUN) and creatinine in the Clinic of Small Animal Medicine, Faculty 
of Veterinary Medicine, Ludwig-Maximilians-Universität München. 
 
2.2.28 Statistical analysis 
Statistical analysis of the results (mean ± SEM) was evaluated by unpaired t test: *p<0.05; 
**p<0.01; ***p<0.001. 
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3 Results 
3.1 Glutamylated MTX-conjugated nanoplexes 
3.1.1 Oligomer structures  
 
This chapter has been partly adapted from: 
D.J. Lee, E. Kessel, D. Edinger, D. He, P.M. Klein, L. Voith von Voithenberg, D.C. Lamb, U. 
Lächelt, T. Lehto, E. Wagner, Dual antitumoral potency of EG5 siRNA nanoplexes armed with 
cytotoxic bifunctional glutamyl-methotrexate targeting ligand, Biomaterials, 77 (2016) 98-110. 
 
As described previously by Lächelt et al. [50], based on solid-phase-supported synthesis method 
[35, 63] multiple copies of the artificial oligoamino acid succinoyl tetraethylene pentamine (Stp) 
as a cationic backbone were combined together with α-amino acids, PEG segment and 
bifunctional MTX ligand to generate sequence-defined monodisperse peptide-like oligomers for 
siRNA delivery [50] (Figure 3.1.1A). A two-armed structure was linked by lysine, in which each 
arm was composed of 4 Stp and a terminal cysteine. In the center of the two-armed core, PEG 
comprising 24 ethylene oxide units was coupled. MTX was attached via the γ- (638-641), or α-
carboxy group (642) of glutamic acid to the exposed part of the PEG segment. For assessment of 
polyglutamylation-related activity of MTX conjugates, 2 (639), 4 (640) or 6 (641) glutamic acid 
units between the γ-carboxy group of MTX and the PEG segment had been introduced. Structures 
are illustrated in Figure 3.1.1B and listed in Table 3.1.1. For control structures, folate was used as 
non-toxic monofunctional targeting ligand (356) and alanine as a non-functional ligand substitute 
(188). 
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Figure 3.1.1. Polyplexes with bifunctional polyglutamylated MTX ligand for siRNA delivery. (A) Schematic diagram 
of the siRNA polyplex formulation. (B) Overview of the oligomers with MTX polyglutamates. The synthetic 
procedures were described in Lächelt et al. [50]. A two-armed structure was linked by lysine, in which each arm 
composed of 4 Stp and a terminal cysteine. MTX was attached via γ- (638-641), or α-carboxy group (642) to the 
exposed part of the PEG segment. “K” represents lysine. “+” in gray represents a cationic oligoamino acid building 
block (Stp). “~” represents dPEG24 motifs.  
 
 
Table 3.1.1. The sequences of oligomers.a 
Oligomer Sequence (CN) Abbreviation 
188 A-dPEG24-K(Stp4-C)2 A-Stp 
356 C-Stp4-K(Stp4-C)-dPEG24-FolA FolA-Stp 
638 K(dPEG24-MTX)-K(Stp4-C)2 MTX-Stp 
639 K(dPEG24-E2-MTX)-K(Stp4-C)2 2E-MTX-Stp 
640 K(dPEG24-E4-MTX)-K(Stp4-C)2 4E-MTX-Stp 
641 K(dPEG24-E6-MTX)-K(Stp4-C)2 6E-MTX-Stp 
642 K(dPEG24-αMTX)-K(Stp4-C)2 αMTX-Stp 
a A, alanine; C, cysteine; E, glutamic acid; K, lysine; Stp, succinoyl tetraethylene pentamine; dPEG24, poly(ethylene 
glycol); FolA, folic acid; MTX, methotrexate. Details can be found in [50]. 
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3.1.2 Physicochemical characteristics of MTX-conjugated siRNA polyplexes 
siRNA was formulated with MTX conjugates at different N/P ratios and measured the particle 
sizes by fluorescence correlation spectroscopy (FCS). As shown in Table 3.1.2 and Figure 3.1.2, 
the hydrodynamic diameter for different oligomers at N/P 16 was ranging between 5.2 to 6.6 
nm. Similarly, polyplexes formed at different N/P ratios did not affect the size significantly, for 
example, MTX conjugate 640 formed polyplexes with the size between 5.6 to 6.4 nm at 
different N/P ratios (Figure 3.1.3).  
 
 
 
 
 
Table 3.1.2. Hydrodynamic diameter (dh) of polyplexes loaded with Cy5-labeled siRNA at different N/P ratios 
determined by fluorescence correlation spectroscopy (FCS).  
 Oligomer N/P dh (nm)c Diffusion Coefficient (µm²/s) 
 Cy5-siRNA - 4.6 ( ± 0.2) 96 ( ± 2) b 
 356 
16 
6.6 ( ± 0.3) 66 ( ± 1) a 
 638 5.6 ( ± 0.3) 79 ( ± 1) a 
 639 5.6 ( ± 0.3) 78 ( ± 1) a 
 641 5.2 ( ± 0.2) 86 ( ± 2) a 
 
640 
3 5.6 ( ± 0.3) 79 ( ± 1) a 
 10 6.2 ( ± 0.3) 70 ( ± 2) a 
 16 6.4 ( ± 0.3) 68 ( ± 1) a 
 20 5.8 ( ± 0.3) 75 ( ± 2) a 
 28 5.8 ( ± 0.3) 75 ( ± 2) a 
a Errors for the diffusion coefficients are given as Jacobians of the fit. They do not contain any information about 
systematic deviations. 
b The error for Cy5-siRNA was determined from six independent measurements of the siRNA. 
c The absolute errors of the hydrodynamic diameters of the polyplexes were calculated as described in supplementary 
methods in [53]. The experiments were performed in collaboration with Dr. Lena Voith von Voithenberg (Department 
of Chemistry, Ludwig-Maximilians-Universität München). 
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Figure 3.1.2. FCS measurements of Cy5-labeled polyplexes at N/P 16 in comparison to free Atto655 and Cy5-siRNA 
(Cy5-siAHA1). (A) As an overview, the normalized autocorrelation functions and weighted residuals for the fitted 
data for free Cy5-siRNA, and 356, 638, 639, 641, and 642 polyplexes. (B-F) Comparison of normalized 
autocorrelation functions of Atto655, Cy5-siRNA, and (B) 356, (C) 638, (D) 639, (E) 641, (F) 642 polyplexes. The 
experiments were performed in collaboration with Dr. Lena Voith von Voithenberg (Department of Chemistry, 
Ludwig-Maximilians-Universität München). 
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Figure 3.1.3. FCS measurement of Cy5-labeled 640 polyplexes at different N/P ratios in comparison to free Cy5 and 
Cy5-siRNA (Cy5-siAHA1). (A) As an overview, the normalized autocorrelation functions and weighted residuals 
for the fitted data of free Cy5-siRNA, and 640 polyplexes at different N/P ratios. (B-F) Comparison of normalized 
autocorrelation functions of Cy5, Cy5-siRNA, and the polyplexes at (B) N/P 3, (C) N/P 10, (D) N/P 16, (E) N/P 20, 
and (F) N/P 28. The experiments were performed in collaboration with Dr. Lena Voith von Voithenberg (Department 
of Chemistry, Ludwig-Maximilians-Universität München). 
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Previous findings indicated that such very small oligomer/siRNA nanoplexes are not suitable for 
standard analysis by dynamic laser light scattering (DLS) [64-66]. Therefore, to further study the 
morphology of 640 siRNA polyplexes, we carried out atomic force microscopy (AFM) and 
transmission electron microscopy (TEM) measurements. As shown in Figure 3.1.4 and 3.1.5, these 
images indicated the formation of homogeneous spherical nanoparticles with size (7.7 ± 0.8 nm 
by AFM; 6.8 ± 0.2 nm by TEM) in a range similar to the FCS measurements. Also in the FCS 
experiments, no aggregation was observed for these polyplexes. Hence, all evidence indicates that 
the siRNA polyplexes were shielded and stable. 
  
 
Figure 3.1.4. AFM images of siRNA polyplexes at N/P 16: (A) 356 polyplexes (arrows): d = 5.3 ± 0.6 nm; (B) 640 
polyplexes (arrows): d = 7.7 ± 0.8 nm. The light intensity reflects the height of nanoparticles. The scale bars represent 
50 nm. The experiments were performed in collaboration with Dr. Rong Zhu (Institute of Biophysics, Johannes-
Kepler-Universität Linz). 
 
 
Figure 3.1.5. TEM image of 640 siRNA polyplexes at N/P 16. d = 6.8 ± 0.2 nm. The scale bar represents 20 nm. The 
experiment was performed in collaboration with Susanne Kempter (Faculty of Physics, Ludwig-Maximilians-
Universität München). 
 
 
To examine the effect of PEGylation on the surface charge of polyplexes, zeta potential of 
polyplexes at various N/P ratios was measured (Table 3.1.3). At N/P 16, zeta potential values of 
the ligand-equipped polyplexes remained close to neutrality, with a distribution between 0.2 to 
2.5 mV. In the case of 640, at N/P 3, the zeta potential was 0.03 mV, and remained close to neutral 
with increasing N/P ratio. Finally, even at very high ratio of oligomer over siRNA (N/P 28), the 
zeta potential was neutral, suggesting that PEGylation successfully shielded the surface charge of 
siRNA polyplexes. 
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Table 3.1.3. Zeta potential values of siRNA polyplexes at different N/P ratios determined by dynamic light scattering 
(DLS) measurements.  
 Oligomer N/P Zeta Potential (mV) 
 638 
16 
0.9 ( ± 0.3) 
 639 0.2 ( ± 0.2) 
 641 0.6 ( ± 0.1) 
 642 2.5 ( ± 1.2) 
 
640 
3 0.03 ( ± 0.04) 
 10 -3.5 ( ± 0.6) 
 16 1.3 ( ± 0.8) 
 20 3.1 ( ± 0.4) 
 28 -1.6 ( ± 0.9) 
 
3.1.3 MTX as targeting ligand for receptor-mediated uptake 
It is recognized that folates and antifolates are mainly internalized into the cells either through 
folate receptor (FR) or reduced folate carrier (RFC). To validate targeting capacity of the MTX-
conjugated siRNA polyplexes, we used fluorescent Cy5-labeled siRNA, and studied the binding 
profile with flow cytometry. To investigate selective targeting ability of MTX conjugates against 
FR, we sought to take advantage of the two cancer cell lines, FR-α-rich KB cells [67] and FR-
deficient A549 cells [68-70]. Comparison of relative binding efficiency of fluorescently labeled 
folate in both cell lines is shown in Figure 3.1.6. 
 
 
 
 
 
Figure 3.1.6. Binding activity of fluorescein-labeled folate ligand in different cell lines measured by flow cytometry. 
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KB and A549 cells were treated with MTX-based 640 siRNA polyplexes, folate-based 356 siRNA 
polyplexes and non-targeted alanine control 188 siRNA polyplexes formed at N/P 16 for 45 min 
on ice, and then binding of the polyplexes was analyzed by flow cytometry (Figure 3.1.7). For the 
alanine-substituted control 188, siRNA polyplexes barely bound to both cell lines (< 1 % positive 
cells). Generally, the folate-substituted control conjugate 356 and MTX oligomer conjugates 
(638-642) exhibited strong cellular association in FR-rich KB cells. The binding rate of 
tetraglutamyl-MTX conjugate 640 (67%) was comparable to that of folate substituted control 
conjugate 356 (71%). The binding levels for the rest of MTX conjugates in KB cells were similar, 
which were lower than the level for 356. On the other hand, in FR-deficient A549 cells, the uptake 
capacity of 356 was significantly reduced (18% positive cells), and MTX conjugates (638-642) 
all failed to bind to the A549 cells (< 3% positive cells), supporting the FR-specific cellular 
association with MTX conjugates.  
 
Figure 3.1.7. The receptor association capacity of MTX conjugates (638-642) was evaluated by comparing the 
binding of siRNA polyplexes by FR-overexpressing KB vs. FR-deficient A549 cells. The amount of Cy5-positive 
cells was analyzed through excitation of the dye at 635 nm and detection of emission at 665/20 nm by flow cytometry. 
188 as a negative alanine substituted control, and 356 as folate-conjugated control were used for comparison with 
MTX conjugates. 
 
To prove that the binding of the polyplexes to the cells is ligand-dependent, the competition assay 
with free ligands was carried out. For this, KB cells were pretreated with folate or MTX, and then 
treated the cells with 640 siRNA polyplexes or 356 siRNA polyplexes. As implicated by flow 
cytometry analysis (Figure 3.1.8), if KB cells were pre-incubated with excess of free MTX (100 
μM), uptake level of MTX conjugate 640 was reduced by 53%, as MTX ligands of 640 competed 
with free MTX for limited receptors. Since FR has several-hundred-fold higher binding affinity 
for folate than for MTX [71], cellular uptake of folate conjugate 356 was not influenced by free 
MTX. Nevertheless, in the presence of free folate (100 μM), cellular binding of 356 and 640 was 
almost completely inhibited by 90% and 99%, respectively. In comparison, the binding capacity 
of alanine control 188 was extremely low under either condition. Based on the observations that 
the MTX conjugates bind to the FR-expressing KB cells in a receptor-specific fashion, and the 
binding was reversed by pre-incubation with excess free folate or MTX, these cellular association 
studies demonstrated that MTX oligomer conjugates target the KB cells mainly through the FR. 
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Figure 3.1.8. The ligand competition study of MTX conjugate (640), folate conjugate (356) and untargeted conjugate 
(188) in the presence of excess free MTX or folate evaluated by flow cytometry. KB cells were treated with (A) 
siRNA polyplexes for 4 h, or  (B) pre-incubated with 100 μM of MTX or (C) 100 μM of folic acid for 30 min before 
incubation with siRNA polyplexes for 4 h. siRNA polyplexes were formed at N/P 16 using Cy5-labeled siRNA. (D) 
The internalization profile for the ligand competition study. The amount of Cy5-positive cells was analyzed through 
excitation of the dye at 635 nm and detection of emission at 665/20 nm. 
 
3.1.4 Gene silencing efficiency 
After showing that the MTX-modified oligomer/siRNA polyplexes utilized FR for cellular 
association, next their ability to be taken up by the cells and induce target gene silencing was 
measured. To validate this, siRNA targeting eGFP (siGFP) or control siRNA (siCtrl) to transfect 
the cells stably expressing eGFP-Luciferase (eGFPLuc) fusion protein was used, and gene 
silencing of siRNA polyplexes via luciferase activity was evaluated by luminometric analysis. 
Previous studies with similar oligomers indicated that these siRNA polyplexes faced the problem 
of endosomal degradation—they are too small to effectively release into the cytosol [33]. Hence, 
to improve endosomal escape of siRNA polyplexes, the influenza virus haemagglutinin subunit 2 
(HA2) variant Inf7 as pH-specific endosome fusion peptide was coupled to the 5' end of siRNA 
sense strand [33, 72]. As shown in Figure 3.1.9, glutamyl-MTX conjugates (638-642) containing 
Inf7-modified siGFP (siGFP-Inf7) at N/P 16 exhibited significant gene silencing efficiency in 
KB/eGFPLuc cells, as 84-93% of luciferase activity was suppressed. Among MTX conjugates, 
640 (4E-MTX-Stp) polyplexes provided the most potent gene silencing activity (93%). In contrast, 
there was no silencing effect for siRNA polyplexes of alanine control 188, furthermore 
highlighting the specificity provided by the MTX targeting ligand. The luciferase activity in 
KB/eGFPLuc cells treated with controls, including siCtrl-Inf7 polyplexes, siGFP without Inf7 or 
plain MTX oligomers were similar, 49-67% compared to untreated cells (Figure 3.1.9 and 3.1.10).  
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Figure 3.1.9. Gene silencing efficiency of MTX conjugates containing eGFP-targeted siRNA (siGFP) or control 
siRNA (siCtrl) in KB cells expressing eGFPLuc protein (KB/eGFPLuc cells). MTX conjugates were incorporated 
with different glutamic acid units (638-642) at N/P 16. Plain oligomers were added in concentrations corresponding 
to the concentrations of the respective polyplexes at the indicated N/P values. siRNA was modified with the 
endosomolytic peptide Inf7.  
 
 
Figure 3.1.10. Gene silencing efficiency with siGFP or siCtrl (both without Inf7 peptide) in FR-overexpressing 
KB/eGFPLuc cells or FR-deficient MCF-7/eGFPLuc cells using MTX conjugate (640) or alanine substituted control 
(188) at different N/P ratios. 
 
 
Figure 3.1.11. Gene silencing efficiency in FR-overexpressing KB/eGFPLuc cells (left) or FR-deficient MCF-
7/eGFPLuc cells (right) using MTX conjugate (640) at different N/P ratios. siRNA was modified with the 
endosomolytic peptide Inf7.  
 
  
 35 
 
Results 
Instead of displaying a RNAi effect, the reduced luciferase activity here demonstrated the intrinsic 
cytotoxicity of MTX ligands by inhibiting DHFR. Looking at Figure 3.1.11, in KB/eGFPLuc cells, 
silencing activity of tetraglutamylated MTX analogue 640 was increased while N/P ratio was 
higher; however, the luciferase expression level in cells treated with siCtrl-Inf7 was not altered at 
various N/P ratios. More importantly, in comparison with FR-positive KB/eGFPLuc cells, 
transfections with folate conjugate (356) or MTX conjugate (640) containing siGFP-Inf7 in FR-
negative MCF-7/eGFPLuc cells did not have any impact on luciferase expression or possible 
cytotoxicity. Taken together, the gene silencing assay further indicated that MTX targeting allows 
the siRNA polyplexes to access the cytoplasm of the cells via specific FR-mediated endocytosis. 
MTX-conjugated oligomers complexed with Inf7-modifed siRNA, especially 640, showed not 
only striking targeted gene-specific silencing ability, but also tissue-specific cytotoxic potential 
mediated by glutamylated MTX. 
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3.1.5 Augmented cytotoxicity by MTX conjugates and EG5 gene knockdown 
As mentioned above, MTX conjugates facilitate their cytotoxic effects by inhibiting DHFR, and 
the inhibition potency is attributed to the glutamylation degree of MTX conjugates [50]. The next 
question is, whether the cytotoxicity could be enhanced by using MTX-conjugated oligomers in 
combination with antitumoral siRNA. For this purpose, MTX-conjugated oligomers were 
exploited to carry siRNA against EG5 (siEG5-Inf7), which is able to block mitosis. As shown in 
Figure 3.1.12A, MTT assay reflected that all glutamyl-MTX conjugates were cytotoxic in FR-
expressing KB cells compared to alanine (188) or folate-substituted control (356). The 
cytotoxicity of the conjugates was elevated with an increasing degree of polyglutamylation, and 
notably, 639 (2E-MTX-Stp), 640 (4E-MTX-Stp) and 641 (6E-MTX-Stp) were more toxic 
compared to free MTX. Meanwhile, in FR-negative MCF-7 cells, no similar cytotoxic effects 
induced by MTX-conjugated or folate-substituted oligomers were found (Figure 3.1.13 and 
3.1.14). 
 
 
Figure 3.1.12. Transfection with Inf7 peptide-modified EG5-targeted siRNA (siEG5-Inf7) or control siRNA (siCtrl-
Inf7) polyplexes at N/P 16 in KB cells. (A) MTT assay in KB cells after transfection with MTX conjugates (638-642), 
alanine conjugate (188) or folate conjugate (356). Free MTX or plain oligomer was applied in concentration 
corresponding to that of siRNA polyplexes. (B) mRNA level of EG5 gene measured by qRT-PR after transfection 
with MTX conjugate (640) or folate control (356). GAPDH was used as housekeeping gene. (C) KB cells treated 
with MTX conjugate (640), alanine conjugate (188) or folate conjugate (356) polyplexes observed under the 
fluorescent microscope. The mitotic blockade that was induced by EG5 knockdown caused "aster formation" of 
nuclear DNA (arrows). DAPI stain. The scale bars represent 10 μm.  
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It was further examined whether co-delivery of MTX conjugates and siEG5-Inf7 could potentiate 
the cytotoxic effect. As seen in Figure 3.1.12A, similar correlation between glutamylation degree 
and siEG5-induced cytotoxicity was found. Among the MTX conjugates, 640 (4E-MTX-Stp) and 
641 (6E-MTX-Stp) polyplexes provided the highest potency to reduce cell viability of KB cells. 
As compared to free MTX or 356 siEG5-Inf7 polyplexes, MTX-conjugate siEG5-Inf7 polyplexes 
induced significantly superior cytotoxicity. Next, EG5-specific gene silencing was confirmed at 
mRNA level by qRT-PCR in KB cells (Figure 3.1.12B), where the tetraglutamyl variant 640 
triggered very efficient downregulation of EG5 mRNA level, while it was significantly more 
potent than the folate-substituted control 356 (p< 0.01). Finally, functional EG5 gene silencing 
was confirmed via aster formation of nuclear DNA, where downregulation of EG5 induced a 
mitotic arrest in KB cells which had been transfected with 640 siEG5-Inf7 polyplexes or 356 
siEG5-Inf7 polyplexes (Figure 3.1.12C). These results clearly indicated efficient silencing of EG5 
expression at mRNA level, followed by mitotic blockade and finally cell death in KB cells. 
Moreover, it suggested that augmented tumor cell killing ability was mediated by a dual 
mechanism combining glutamyl-MTX oligomer with antitumoral siRNA. 
 
 
Figure 3.1.13. MTT assay in MCF-7 cells treated with MTX or oligomers 356, 638, 639, 640, 641 at concentration 
between 1 - 104 nM for 48 h. 
 
 
Figure 3.1.14. MTT assay in MCF-7 cells treated with MTX, oligomer or polyplexes (at 370 nM of siEG5-Inf7 or 
siCtrl-Inf7) for 24 h.  
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3.1.6 Prolonged intratumoral retention 
The half-life of siRNA in vivo is short, predominantly due to rapid elimination by renal filtration 
and biodegradation by RNases [73]. For example, our group previously reported that intratumoral 
retention of free siRNA lasts merely for 4 h [33]. From the previous work with analogous folate-
PEG siRNA polyplexes, we know that these small (<10 nm) nanoparticles are stable in the blood 
upon systemic i.v. injections, but rapidly eliminated via kidneys, with recovery of intact 
polyplexes from urine (Figure S16 and S17 in Dohmen et al. [23]). For this reason, both in the 
previous and the current study intratumoral injection (i.t.) was the selected route of administration. 
 
 
Figure 3.1.15. Intratumoral distribution of siRNA polyplexes at N/P 16 in NMRI-nude mice bearing KB xenograft 
tumors determined by NIR fluorescence bioimaging. (A) Time-dependent retention of 50 μg of Cy7-labeled siRNA 
after intratumoral injection using MTX-conjugated oligomer 640 (upper panel), folate-conjugated control 356 
(middle panel) or alanine substituted control 188 (lower panel) as carrier. (B) Harvested tumor samples at 168 h after 
injection of siRNA polyplexes. Experiments were performed in triplicates; a representative animal of each group is 
shown. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of 
Pharmacy, Ludwig-Maximilians-Universität München). 
 
 
To further examine whether MTX-conjugated oligomers could enhance the retention of siRNA 
within the tumor, Cy7-labeled siRNA formulated with 640 at N/P 16 was administered i.t. to KB 
tumor-bearing mice. The biodistribution study with Cy7-labeled siRNA measured by near infrared 
(NIR) fluorescence imaging (Figure 3.1.15A) showed that the conjugation of MTX as targeting 
ligand significantly increased the tumoral retention of siRNA. Both targeted siRNA polyplexes 
(640 and 356) carried out remarkably longer retention (5 days) than that of untargeted 188 siRNA 
polyplexes by ~120 h. The MTX-based 640 siRNA polyplexes showed comparable retention as 
folate-based 356 siRNA polyplexes, and Cy7-labeled siRNA was still detectable 168 h after 
injection (Figure 3.1.15B). The biodistribution study provided evidence that these siRNA 
polyplexes were eliminated through renal clearance (Figure 3.1.16). 
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Figure 3.1.16. Renal clearance of siRNA polyplexes in tumor-bearing NMRI-nude mice determined by NIR 
fluorescence bioimaging. After intratumoral injection using MTX-conjugated oligomer 640 (upper panel), folate-
conjugated control 356 (middle panel) or alanine-substituted control 188 (lower panel) as carrier, Cy7-labeled siRNA 
was detected in the kidneys and the bladder. Experiments were performed in triplicates; a representative animal of 
each group is shown. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, 
Department of Pharmacy, Ludwig-Maximilians-Universität München). 
 
3.1.7 Dual in vivo therapeutic effects by MTX-conjugated siRNA polyplexes 
After confirming that FR-targeted siRNA polyplexes were well-retained in the tumor tissue, we 
further investigated the therapeutic potential of these polyplexes. For this, we formulated 
polyplexes of the tetraglutamyl-MTX conjugate 640 with siEG5-Inf7 or siCtrl-Inf7, free 640 
(without siRNA), or polyplexes of the folate conjugate 356 with siEG5-Inf7, and administered 
these formulations i.t. in the KB tumor-bearing nude mice. In line with previous intratumoral 
administration studies, 50 µg of siRNA (diluted in 50 µL of HBG) was applied [33, 36]. To avoid 
unspecific immune reactions, we used 2' OMe-modified siRNA that is designed not to trigger toll-
like receptor (TLR)-mediated immune responses [29, 30]. The post-treatment survival was 
recorded to provide Kaplan–Maier survival analysis. All animals treated with siRNA polyplexes 
showed significantly reduced tumor growth compared to untreated controls (Figure 3.1.17A). 
Importantly, combination treatment with 640 siEG5-Inf7 polyplexes nearly completely inhibited 
tumor growth 8 days after the treatment (Figure 3.1.17B), and all of these animals still showed no 
palpable or measurable tumor 17 days after the treatment (Figure 3.1.18). Encouragingly, three 
animals receiving 640 siEG5-Inf7 polyplexes have survived without recurrence until the study 
was ended (day 70) (Figure 3.1.17C). In addition, 640 siCtrl-Inf7 polyplexes induced superior 
effect over free 640 to inhibit tumor growth. With regard to antitumoral efficacy, the big difference 
between the EG5 and the control siRNA group 640 siCtrl-Inf7 polyplexes ruled out a significant 
contribution of immune reactions to the therapeutic effect. Nevertheless, 640 siCtrl-Inf7 
polyplexes mediated higher antitumoral effect than that of free 640 (i.e. without siRNA 
complexation) to inhibit tumor growth. Possible explanations could be better intratumoral 
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retention of multiple conjugated MTX ligands by 640 siRNA-Inf7 nanoparticle formation, or 
improved cytosolic delivery of the MTX molecules facilitated by the endosomolytic Inf7 peptide. 
Interestingly, 356 siEG5-Inf7 polyplexes resulted in comparable effect in terms of tumor 
suppression and survival time as free 640 (30.8 ± 2.3 days vs. 29.7 ± 2.4 days). 
 
Figure 3.1.17. In vivo validation of augmented antitumoral effect by MTX-conjugated siRNA polyplexes. (A) 
Therapeutic efficacy of MTX-conjugated 640 polyplexes (with siEG5-Inf7 or siCtrl-Inf7), free oligomer 640 (without 
siRNA), or folate-conjugated 356 siEG5-Inf7 polyplexes in KB xenograft (n = 6 per group). The insert shows a 
comparison of the tumor volume in different groups 5 days after the last treatment (day 22). (B) Representative KB 
tumor lesions from the cohorts in (A) on day 25. (C) The Kaplan–Maier survival curve of the animals treated with 
indicated formulations. In the animals receiving 640 siEG5-Inf7 polyplexes, tumors largely disappeared by day 22, 
and in 3 animals no recurrence was observed until the end of the study (day 70). The experiments were performed in 
collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität 
München). 
  
Time after KB cell implantation (Day) 
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Figure 3.1.18. KB tumor-bearing animals were administered i.t. with 640 siRNA polyplexes (with siEG5-Inf7 or 
siCtrl-Inf7, and the tumor sizes were measured 1 day (day 18) or 17 days (day 30) after the last treatment. No palpable 
or measurable tumor was found on day 30 in the animals treated with 640 siEG5-Inf7. The experiments were 
performed in collaboration with Eva Kessel (Dr. med. vet., Department of Pharmacy, Ludwig-Maximilians-
Universität München). 
 
In the tumors treated with 640 siEG5-Inf7 polyplexes or 356 siEG5-Inf7 polyplexes, necrotic 
tumor tissue accompanied by an active healing process was observed. In general, scars started to 
fade and thin out gradually after the treatments (Figure 3.1.19). At the same time, equivalent 
intratumoral dosages of free MTX did not reduce tumor growth (Figure 3.1.20). Moreover, 
monitoring of body weights demonstrated that the treatment was well tolerated (Figure 3.1.21). 
Temporary stagnation of body weight (days 11–18) in the treated animals was possibly due to 
tumor necrosis-associated discomfort, and a rapid gain of weight after the treatments was noted. 
These results suggest that the tetraglutamyl-MTX ligand provides tumor-suppressive potential, 
and effective EG5 silencing by FR-targeted polyplexes represents a potential strategy for tumor 
treatment, which can be further combined with MTX-conjugated 640 for improved therapeutic 
efficacy. 
 
 
Figure 3.1.19. The necrotic tumor tissue followed by an active healing process was found in the KB tumor-bearing 
animals treated with 640 siEG5-Inf7 polyplexes or 356 siEG5-Inf7 polyplexes. The healing process could be different 
for different individuals, while the wounds were eventually repaired as shown in the representative pictures from the 
animals treated with 640 siEG5-Inf7 polyplexes. 
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Figure 3.1.20. Tumor growth curve after the intratumoral injection of free MTX or glutamyl-MTX conjugate 640 in 
KB xenografts (n = 6 per group). (A) Therapeutic efficacy of free MTX or free oligomer 640. (B) The Kaplan–Maier 
survival curve of the animals receiving indicated formulations. The experiments were performed in collaboration 
with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München). 
 
 
Figure 3.1.21. The body weights of the animals receiving different formulations were monitored on a daily basis 
until the animals were sacrificed. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. 
study, Department of Pharmacy, Ludwig-Maximilians-Universität München). 
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3.2 Targeted combinatorial polyplexes (TCPs) 
3.2.1 Formation of TCPs 
 
This chapter has been partly adapted from: 
D.J. Lee*, D. He*, E. Kessel, K. Padari, S. Kempter, U. Lächelt, J.O. Rädler, M. Pooga, E. Wagner, 
Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes, J Control Release, 
244 (2016) 280–291 (shared first authorship). 
 
Based on previous studies, four oligomers were selected from the library to generate novel 
combinatorial formulations for targeted siRNA delivery (Scheme 3.2). This work was performed 
in collaboration with Dr. Dongsheng He (PhD study, Department of Pharmacy, Ludwig-
Maximilians-Universität München). Three-arm Stp oligomers 386 and 689, were chosen for their 
strong siRNA binding ability, which provide a highly stable cationic core to compact siRNA [35, 
36, 74]. Moreover, PEG-folate-conjugated Sph oligomers (4-arm) 709 and (2-arm) 717, were used 
for FR targeting and surface shielding [75]. Here we combined these two types of oligomers, in 
order to optimize the siRNA polyplexes by co-formulation. All oligomers contain terminal 
cysteines with free thiol groups for subsequent disulfide formation within siRNA polyplexes. As 
standard disulfide formation by air oxidation has been found to be a rather slow and incomplete 
process, we intended to make this step faster and more specific. Therefore, we activated the thiol 
groups of oligomer #1 with 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) to produce TNB-
modified oligomer (Figure 3.2.1A). The TNB-modified oligomer formed a binary siRNA polyplex 
with siRNA, and in the following incubation with the unmodified thiol-oligomer #2 it would 
undergo a fast uni-directional coupling through disulfide formation with the free thiol groups of 
thiol-oligomer #2 in three dimensions, resulting in hypothetic nanogel structures (Scheme 3.2). 
The combination of siRNA with both oligomers thus generated targeted combinatorial polyplexes 
(TCPs), which were composed of compact cationic core for siRNA binding, well-shielded PEG 
layer and folates as targeting ligands (Figure 3.2.1B). TCPs were optimized by testing different 
TNB-modified oligomers #1 / unmodified thiol oligomers #2 at various molar ratios, and by 
evaluating three different siRNA / oligomer #1 / oligomer #2 mixing sequences. Preliminary gene 
silencing experiments (Figure 3.2.2) demonstrated that tested mixing sequences presented similar 
efficiencies as the first alternative (pre-incubated siRNA with the TNB-modified oligomer #1, 
followed by disulfide exchange reaction with thiol oligomer #2). For practical reasons, all further 
testing was performed with this mixing sequence. 
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Figure 3.2.1. Targeted combinatorial polyplexes (TCPs) with folate ligand for siRNA delivery. (A) TNB-modified 
oligomer #1 was obtained by reacting the solid-phase derived thiol precursor oligomer #1 with 10 eq of DTNB for 2 
h at room temperature. The incubation of TNB-modified oligomer #1 with siRNA formed a binary polyplex. Addition 
of thiol-oligomer #2 resulted in fast uni-directional coupling of TNB-modified oligomer #1 through disulfide 
formation with the free thiol groups of #2. In this way siRNA, TNB-modified oligomer and unmodified thiol-oligomer 
were formulated to produce a TCP. (B) Schematic presentation of key elements of a TCP. Endosomolytic Inf7 peptide 
was conjugated to siRNA for enhanced endosomal escape [33].  
 
 
 
As a result, four combinatorial formulations, TCP1, TCP2, TCP3 and TCP4, were developed 
(Scheme 3.2). TCP1 and TCP3 shared the similar combined structure of 386 + 709 (Scheme 3.2 
top); TCP2 and TCP4 shared the similar combined structure of 689 + 717 (Scheme 3.2 bottom). 
Differences rose from the alterative TNB-activations of oligomers. After systematic screening and 
evaluating different molar ratios of oligomers (Tables S1-S4 in [76]), equal molar (1:1) oligomer 
ratios at N/P 16 was determined as most useful for the subsequent experiments. 
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 TCP1 TCP3 
TNB-
Oligomer #1 
(4-arm 873) 
K-(PEG24-Folate)-K-[K-(Sph4-C-TNB)2]2 
(N/P 11.2) 
(3-arm 769) 
TNB-C-Stp3-K-(Stp3-C-TNB)2 
(N/P 4.8) 
Thiol-
Oligomer #2 
(3-arm 386) 
C-Stp3-K-(Stp3-C)2 
(N/P 4.8) 
(4-arm 709) 
K-(PEG24-Folate)-K-[K-(Sph4-C)2]2 
(N/P 11.2) 
Combined 
Structure 
 
(709-S-S-386-S-S)x 
 TCP2 TCP4 
TNB- 
Oligomer #1 
(3-arm 770) 
TNB-C-H-(Stp-H)3-K-[(H-Stp)3-H-C-TNB]2 
(N/P 7.4) 
(2-arm 874) 
K-(PEG24-Folate)-K-(Sph4-Y3-C-TNB)2 
(N/P 8.6) 
Thiol- 
Oligomer #2 
(2-arm 717) 
K-(PEG24-Folate)-K-(Sph4-Y3-C)2 
(N/P 8.6)  
(3-arm 689) 
C-H-(Stp-H)3-K-[(H-Stp)3-H-C]2 
(N/P 7.4) 
Combined 
Structure 
 
(717-S-S-689-S-S)x 
Scheme 3.2. Targeted combinatorial polyplex (TCP) formulations. siRNA was co-formulated with TNB-modified 
oligomers and unmodified thiol-oligomers at various molar ratios to form the TCP carriers. In most experiments 
polyplexes were formed at N/P 16 using an equal molar oligomer ratio of 1:1; for these conditions the individual N/P 
ratio of each oligomer is presented. The oligomer sequences are indicated (left to right) from C- to N- terminus. C: 
cysteine; H: histidine; K: lysine; Y: tyrosine; S-S: disulfide crosslinking; PEG24: polyethylene glycol; TNB: 5-thio-
2-nitrobenzoic acid; Stp: succinoyl-tetraethylene pentamine; Sph: succinoyl-pentaethylene hexamine. K-( and K-
[ refer to branchings by α- and ε-amino modification of lysines. x: hypothetic nanogel structures resulting from 
disulfide crosslinking in three dimensions within the TCP. 
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Figure 3.2.2. Gene silencing efficiency of TCP1 in KB/eGFPLuc cells using different alternative mixing sequences. 
The siRNA polyplexes were prepared at N/P 16 with 370 nM siRNA: siGFP, siCtrl, siGFP-Inf7 or siCtrl-Inf7. The 
different mixing sequences were compared: Alternative (1), also used for the majority of experiments; the TNB-
modified oligomer solution was pre-incubated with siRNA solution for 30 min, then was incubated with unmodified 
oligomer solution for 40 min. Alternative (2), the TNB-modified oligomer solution and unmodified oligomer solution 
were incubated all together with siRNA solution for 40 min. Alternative (3), unmodified oligomer solution was pre-
incubated with siRNA solution for 30 min, then further incubated with TNB-modified oligomer solution for 40 min. 
 
3.2.2 Physicochemical characterizations 
Formulating TCPs (Scheme 3.2) at N/P 16, we measured the particle sizes by dynamic laser-light 
scattering (DLS) based on different molar ratios of [TNB-modified oligomer #1 / unmodified 
thiol-oligomer #2]. At the ratio of 1:1, the sizes of the two 386 + 709 formulations, TCP1 and 
TCP3, are 104 nm and 209 nm, respectively, whereas the two 689 + 717 formulations, TCP2 and 
TCP4, have a larger size of ~ 400 nm (Table 3.2.1). To examine the effect of PEG shielding on 
the surface charge of TCPs, zeta potentials of siRNA polyplexes at N/P 16 were measured (Table 
3.2.1). For TCP1, TCP2 and TCP4, the zeta potential values were reduced from approximately ≥ 
+20 mV [35] to values around + 8-9 mV. It is interesting that TCP3, comprising the same 
oligomers by a different activation scheme, displayed a highly positive zeta potential of +24 mV.  
 
Formulation Size (nm) PdI Zeta potential (mV) 
TCP1 103.5 ± 0.8 0.239 ± 0.026 9.1 ± 0.2 
TCP2 429.4 ± 53 0.213 ± 0.017 7.93 ± 0.21 
TCP3 208.8 ± 3.4 0.267 ± 0.011 24.3 ± 0.3 
TCP4 398.3 ± 63.5 0.229 ± 0.017 8.1 ± 0.05 
 
Table 3.2.1. Size and zeta potential of TCPs at N/P 16 measured by DLS measurements. [TNB-modified oligomer / 
unmodified thiol-oligomer] molar ratio = 1:1. The experiments were performed by Dr. Dongsheng He (PhD study, 
Department of Pharmacy, Ludwig-Maximilians-Universität München). 
 
To study the morphology of these formulations, we carried out transmission electron microscopy 
(TEM) measurements. As shown in Figure 3.2.3A, these images indicated the formation of 
homogeneous spherical nanoparticles with sizes in a range consistent with the DLS measurements. 
No aggregates were observed for these siRNA polyplexes. Moreover, to validate the siRNA 
binding activity of TCPs, we analyzed the siRNA polyplex formation by agarose gel shift assay 
(Figure S2-5 in [76]). In general, when increasing the fraction of 3-arm Stp oligomers in TCP 
formulations, the siRNA binding was significantly increased. Apparently the 3-arm Stp oligomers 
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were essential for compaction and stability of siRNA polyplexes. At the molar ratio of 1:1, all 
TCP formulations exhibited complete siRNA binding at N/P 16 (Figure 3.2.32B).  
 
 
Figure 3.2.3. Physicochemical assessments of TCPs. (A) TEM images of TCPs at N/P 16. (B) siRNA binding of 
TCPs at N/P 16 determined by agarose gel shift assay. Free siRNA and folate-linked PEGylated oligomer 356 [33] 
were used as controls. 
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3.2.3 Receptor-mediated uptake of TCPs 
As folate retains high affinity for FR 
following derivatization via one of its two 
carboxylate groups [77], folate conjugation 
presents an advantageous strategy for FR-
targeted drug delivery. To validate targeting 
capacity of the folate-linked TCPs, 
fluorescent Cy5-labeled siRNA was used to 
study the cellular internalization profile by 
flow cytometry. To investigate selective 
targeting ability of TCPs against FR, FR-
rich cancer cell lines (murine lymphocytic 
leukemia L1210 cells, murine lung 
carcinoma M109 cells and human cervix 
carcinoma KB cells) and FR-deficient 
human mammary adenocarcinoma MCF-7 
cells [45, 67, 78-80] were applied for the 
following experiments. 
 
Figure 3.2.4. Folate receptor (FR)-mediated uptake 
and intracellular distribution of TCPs. (A) The 
cellular internalization capacity of TCPs was 
evaluated by comparing the cellular internalization of 
siRNA polyplexes into FR-overexpressing M109 and 
L1210 vs. FR-deficient MCF-7 cells. siRNA 
polyplexes were prepared at N/P 16 with Cy5-labeled 
siRNA. The cells were incubated with siRNA 
polyplexes at 37 °C for 4 h before flow cytometric 
measurements. The amount of Cy5-positive cells was 
analyzed through excitation of the dye at 635 nm and 
detection of emission at 665/20 nm. (B-G) Immuno-
TEM of FR-mediated endocytic pathway of TCP1 in 
FR-overexpressing KB cells. TCP1 was formed at 
N/P 16 with biotinylated-siRNA tagged with 10 nm 
neutravidin-gold particles. FR was visualized with 
anti-FR-α antibodies and Protein-G coupled to 6 nm 
gold particles. (B) Association of siRNA polyplexes 
with the cell surface after incubation of cells with 
siRNA polyplexes for 15 min. (C) The colocalization 
of siRNA polyplexes with FR in membrane 
invagination after incubation for 15 min. (D) The FR 
localizing in close proximity to siRNA polyplexes in 
membrane invagination indicated by yellow 
arrowheads or dots in higher-magnification image and 
the scheme of (C), respectively. (E) Colocalization of 
FR (yellow dots) with siRNA polyplexes inside 
endosomal vesicles after incubation for 1 h. (F) The 
higher-magnification image of (E) indicating FR by 
yellow arrowheads. (G) Endosomal structures with 
disrupted membrane, indicating endosomal escape of 
siRNA molecules after incubation for 4 h. The 
experiments were performed in collaboration with Dr. 
Kärt Padari (Institute of Molecular and Cell Biology, 
University of Tartu). 
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The cells were treated with TCPs at N/P 16 for 4 h at 37 °C, and then uptake of siRNA polyplexes 
was analyzed by flow cytometry (Figure 3.2.4A). Generally, all the TCP formulations exhibited 
strong cellular internalization in FR-rich cells. The uptake levels for TCPs in L1210 cells were 
similar (87-95% positive cells), which were higher than the levels in M109 cells (73-86% positive 
cells). In contrast, after transfecting FR-deficient MCF-7 cells with TCPs, the uptake levels were 
very low (5-9%). Hence, the cellular uptake studies demonstrated that folate-conjugated TCP 
formulations were taken up into cells in a receptor-specific fashion, based on the observations that 
siRNA polyplexes efficiently bound to FR-expressing L1210 and M109 cells, and the uptake of 
TCPs diminished in FR-negative MCF-7 cells. To further confirm the involvement of FR in the 
cellular uptake of TCPs, and to gain more detailed insight into how these polyplexes associate 
with receptors and how they are endocytosed by cells, immuno-TEM was used [81]. These studies 
were performed during a research visit at Institute of Molecular and Cell Biology, University of 
Tartu. For detecting the colocalization of TCPs and FR, we used different sizes of gold particles 
for immuno-labeling. The primary antibodies against FR were visualized with Protein G-gold 
conjugates (6 nm in diameter), whereas biotinylated siRNA was labeled with neutravidin-gold 
conjugates (10 nm in diameter). Namely, 6 nm-gold probe for detecting FR and 10 nm gold tag 
for detecting siRNA polyplexes should be distinguishable in cells by TEM at ultrastructural scale. 
To examine the internalization process of TCPs starting from their initial binding to the cell 
surface and subsequent intracellular pathway, FR-positive KB cells were incubated with 10 nm 
gold label-containing TCP1 for 15 min, 1 h and 4 h. After incubation for 15 min, siRNA 
polyplexes were detected as electron dense particles associated with the cell surface (Figure 
3.2.4B) and induced invaginations in the plasma membrane of KB cells (Figure 3.2.4C). As 
illustrated in the higher-magnification image we observed the receptors (indicated by arrowheads 
in Figure 3.2.4D) were in close proximity to siRNA polyplexes in endosomal invaginations. At 1 
h, inside cells, most of siRNA polyplexes were entrapped in endosomal structures, where they 
formed large dense TCP1 clusters and some retained association with the membrane of endosomal 
vesicles (Figure 3.2.4E). Although the polyplexes localized in densely packed clusters in the 
endosomal structures, we were able to distinguish some smaller gold particles representing the FR 
that had associated with TCPs (arrowheads in Figure 3.2.4F). In addition, a small fraction of the 
endosomal structures had lost the intactness of its limiting membrane (Figure 3.2.4G) already 
within 4 h and siRNA molecules had escaped from the ruptured vesicles, and infrequently, single 
10 nm gold particles denoting TCPs were detected diffusely in cytosol. In contrast, non-targeted 
siRNA polyplexes were very rarely detected in KB cells or associated with their surface.  
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3.2.4 Gene silencing efficiency of TCPs 
After showing that the folate-conjugated TCPs utilized FR for cellular association and 
intracellular delivery of siRNA, next their ability to induce target gene silencing was evaluated. 
In order to validate this, siGFP or siCtrl was used to transfect the KB/eGFPLuc cells, and gene 
silencing efficiency of siRNA polyplexes was evaluated via luciferase activity by luminometric 
analysis. Former studies of our group indicated that PEGylated siRNA polyplexes, similar as 
several other PEG-shielded polyplexes [82], face the problem of endosomal entrapment into the 
cytosol [33]. For this reason, the synthetic peptide Inf7, previously designed as pH-specific analog 
of the influenza virus hemagglutinin subunit 2 (HA2) N-terminal fusion sequence [72, 83, 84], 
was covalently coupled to siRNA as endosomolytic agent [33, 53, 85]. In this assay, we sought to 
compare the transfection efficiency of TCPs with the previously published 356 [33]. As shown in 
Figure 3.2.5, all the TCP formulations containing Inf7-modified siGFP (siGFP-Inf7) at N/P 16 
mediated significant gene silencing efficiency in KB/eGFPLuc cells, as 75-94% of luciferase 
activity was suppressed. Among these TCP formulations, TCP1 exhibited the most potent gene 
silencing activity (94%), which is comparable to 356 nanoplexes (90%) and superior to the rest 
of TCPs. In contrast, in the cells treated with unmodified siGFP polyplexes, the silencing effect 
was significantly decreased (45-63% for TCPs and 35% for 356), further highlighting that Inf7 
peptide is necessary for sufficient release of siRNA into cytosol, as reported earlier [33, 53, 85].  
 
 
Figure 3.2.5. Gene silencing efficiency of TCPs in KB cells expressing eGFPLuc fusion protein (KB/eGFPLuc cells). 
The siRNA polyplexes were prepared at N/P 16 with different siRNA sequences: eGFP-targeted siRNA (siGFP), 
control siRNA (siCtrl), or siRNA chemically linked with the endosomolytic peptide Inf7 (siGFP-Inf7 or siCtrl-Inf7). 
 
  
 51 
 
Results 
3.2.5 Tumor-specific toxicity mediated by EG5 gene silencing 
As aforementioned, TCPs facilitated functional gene silencing with Inf7-modified siRNA in vitro, 
we next sought to investigate, whether we could mediate tumor-specific cytotoxicity by using 
antitumoral siRNA. For this purpose, we exploited siRNA against EG5 (siEG5-Inf7) that 
corresponds to a sequence of the EG5 coding region conserved between human and mouse, which 
is able to block the formation of bipolar mitotic spindles, causing cell-cycle arrest and induction 
of apoptosis [27]. After incubating the cells with siEG5-Inf7 TCPs, MTT assay revealed that all 
the TCP formulations were cytotoxic to the FR-expressing M109 cells (Figure 3.2.6A). TCP1 and 
TCP2 mediated the higher cell killing (90%; 85%) than TCP3, TCP4 or the folate-conjugated 356. 
Besides, siCtrl-Inf7 TCPs did not affect cell viability of M109 cells. Meanwhile, in FR-negative 
MCF-7 cells, there’s no similar cytotoxic effect induced by TCPs (Figure 3.2.6B). Moreover, 
functional EG5 gene silencing was confirmed via aster formation of nuclear DNA, where 
downregulation of EG5 induced a mitotic arrest in siEG5-Inf7-treated M109 cells. After 
incubation with siEG5-Inf7 polyplexes, Figure 3.2.6C showed the typical mitotic figures in 
dividing cells by DAPI staining. No aster formation could be observed after application of control 
siRNA polyplexes. Further examination of EG5-specific gene silencing at mRNA level was 
performed by qRT-PCR in FR-expressing L1210 cells. Figure 3.2.6D revealed that all the siEG5-
Inf7 TCPs triggered very efficient downregulation of EG5 Mrna levels, while TCP1 was 
significantly more potent than the rest of formulations. In the siCtrl-Inf7-treated cells, the mRNA 
expression levels were similar to untreated cells, which also reflected that there was no off-target 
effect by TCPs. Therefore, these results clearly supported that folate-conjugated TCPs enabled 
efficient silencing of EG5 gene expression at mRNA level, followed by mitotic blockade and 
finally cell death in FR-positive cells. 
 
Figure 3.2.6. Cell transfections with 
TCPs containing Inf7 peptide-
modified EG5-targeted siRNA 
(siEG5-Inf7) or control siRNA 
(siCtrl-Inf7) at N/P 16. MTT assay in 
(A) FR-positive M109 cells and (B) 
FR-negative MCF-7 cells after 
transfection with TCPs. (C) M109 
cells treated with TCPs visualized by 
fluorescence microscopy after DAPI 
staining of DNA. The mitotic 
blockade that was induced by EG5 
knockdown caused "aster formation" 
of nuclear DNA (arrowheads). The 
scale bars represent 10 μm. (D) 
mRNA level of EG5 gene measured 
by qRT-PCR after transfection of 
TCPs in FR-positive L1210 cells. 
GAPDH was used as housekeeping 
gene. 
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3.2.6 Distribution of TCPs in tumor-bearing mice upon systemic administration 
Upon systemic administration, unmodified siRNA is easily eliminated via renal clearance because 
of the small size, thus the half-life of siRNA in vivo is very short (few minutes) [86]. Moreover, 
it can also be enzymatically degraded by endogenous RNases with a serum half-time ranges from 
several minutes to 1 h [87]. To investigate whether TCPs could improve the distribution profile 
of siRNA, TCP1, the most potent formulation in vitro with favorable size and surface charge, was 
selected for the further in vivo studies. The two single oligomer components of TCP1, i.e. 3-arm 
Stp-based oligomer 386 and DTNB-modified 4-arm PEGylated folate-equipped Sph oligomer 873, 
were used for comparison. FR-expressing L1210 tumor cells were implanted subcutaneously in 
nude mice. We formulated different Cy7-labeled siRNA (50 µg of siRNA) polyplexes at N/P 16, 
and administered these siRNA polyplexes intravenously (i.v.). The biodistribution of Cy7-labeled 
siRNA measured by near infrared (NIR) fluorescence imaging (Figure 3.2.7A) showed that for 
TCP1 the systemic distribution of Cy7 signal lasted more than 1 h, and in the meanwhile the 
tumoral retention of siRNA was observed. In case of the non-targeted 3-arm Stp-based oligomer, 
Cy7 signal disappeared after ~30 min, and siRNA barely reached the tumor site.  
 
Figure 3.2.7. Biodistribution of siRNA polyplexes at N/P 16 in NMRI-nude mice bearing L1210 tumors determined 
by NIR fluorescence bioimaging. (A) Time-dependent retention of 50 μg of Cy7-labeled siRNA after i.v. injection 
using TCP1, 3-arm Stp oligomer 386, DTNB-modified PEGylated folate-conjugated 4-arm Sph oligomer 873 as 
carriers. Lateral views of animals were shown to present the tumor sites. (B) Tumors harvested 15 min, 1 h or 4 h 
after injection of siRNA polyplexes. (C) Distribution and elimination of TCP1 over 24 h. (D) Tumors and organs of 
TCP1-treated animals harvested 1 h or 24 h after injection of siRNA polyplexes. Experiments were performed with 
3-4 animals per group; a representative animal of each group is shown. The experiments were in collaboration with 
Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München). 
 
 
Additionally, DTNB-modified 4-arm folate conjugate exhibited the first evidence for the tumoral 
retention of siRNA within 15 min, and the systemic distribution was longer than 3-arm Stp-based 
oligomer. As control, free siRNA was rapidly filtered by kidneys within 30 min. Notably, Cy7 
siRNA was detectable in harvested tumors only from TCP1-treated animals at 1 h, while there 
was no Cy7 signal in the rest of groups (Figure 3.2.7B). In TCP1-treated animals, the tumor 
presented the second highest remaining Cy7 signal after the kidneys at 1 h, and both in vivo and 
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ex vivo imaging reflected that siRNA was eliminated through renal clearance within 24 h (Figure 
3.2.7C and D). 
3.2.7 Tumor-targeted EG5 gene silencing in vivo 
After confirming that FR-specific TCP1 successfully delivered siRNA in the tumor tissue via 
systemic administration, we sought to validate the functional gene silencing of TCP1 in vivo. For 
this purpose, we formulated TCP1 with siEG5-Inf7 or siCtrl-Inf7 (50 µg of siRNA) at N/P 16, 
and administered these siRNA polyplexes i.v. in the L1210 tumor-bearing mice twice. 24 h after 
the last treatment, the tumors were harvested. RNA was isolated from tumor tissues, and mRNA 
expression levels of EG5 gene were evaluated by qRT-PCR. Compared to untreated controls, the 
siEG5-Inf7 TCP1 reduced the EG5 gene expression by 46%. Importantly, the siCtrl-Inf7 TCP1 
showed negligible effects on EG5 mRNA level as compared with untreated tumors (Figure 3.2.8 
A).  
 
Figure 3.2.8. Tumor-targeted gene silencing efficiency of TCP1 in L1210 tumor-bearing mice. (A) mRNA level of 
EG5 gene after two-fold i.v. injection of TCP1 with 50 μg of siEG5-Inf7 or siCtrl-Inf7 at N/P 16. (B) Body weight 
development over treatment period. The i.v. injections were performed at day 13 and 14 as indicated by arrows. The 
body weight curves of TCP1-treated animals were compared to that of untreated animals over the same time after 
tumor inoculation. Experiments were performed with 5 animals per group. The experiments were in collaboration 
with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München). 
 
Systemic circulation of siRNA polyplexes might also lead to enhanced exposure to non-target 
tissues which might cause side effects; we thus monitored the body weights and carried out blood 
biochemistry examination as preliminary evaluation of potential side effects. As seen in Figure 
3.2.8B, the body weight curves indicate that the treatments were well-tolerated compared to 
untreated controls. We took blood samples 24 h after the treatments to determine the four clinical 
biochemistry parameters (ALT, AST, BUN and creatinine). Elevated liver enzymes (ALT and 
AST) would indicate formulation-related liver damage or acute hepatitis, while increased BUN or 
creatinine would be related to renal malfunctions. As presented in Table 3.2.2, in the treatment 
groups, liver enzymes were almost equivalent to the untreated control group. In terms of BUN, 
there was no significant elevation, either. Creatinine showed an elevation for TCP1 with siEG5-
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Inf7 treated animals compared to untreated controls, but still these serum values were lower than 
the reference range of female NMRI-nu/nu mice at the same age (data sheet of NMRI-nu/nu, 
Janvier Labs). Therefore, TCP1 exhibited siRNA delivery into the tumor and resulted in EG5 gene 
silencing at mRNA level in the absence of detectable adverse effects. 
 
Table 3.2.2. Clinical biochemistry parameters (ALT, AST, BUN and creatinine). Plasma was obtained from the 
treated animals 24 h after the second injection (n = 5) compared to untreated tumor-bearing mice (n = 3) that were 
euthanized on the same day. 
  ALT (U/L) AST (U/L) Creatinine (mg/dL) BUN (mg/dL) 
TCP1 + siEG5-Inf7 34 ± 15 80 ± 28 0.1 ± 0.01* 43 ± 13 
TCP1 + siCtrl-Inf7 39 ± 2 115 ± 36 0.08 ± 0.02 39 ± 6 
Untreated 46 ± 15 113 ± 23 0.07 ± 0.01 38 ± 7 
* significant difference between untreated control and TCP1 + siEG5-Inf7 treated group. 
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3.3 Targeted lipopolyplexes (TLPs) 
3.3.1 Formation of TLPs 
To prepare targeted lipopolyplexes (TLPs) for siRNA delivery, four oligomers from a recently 
established library of sequence-defined oligomers were chosen (Figure 3.3.1A) [33, 35-37]. 
Among these, the PEG-folate-conjugated Stp oligomer (356) formed neutralized siRNA 
nanoplexes (TEM images shown in Figure 3.3.1B) but with moderate siRNA binding ability 
(Figure 3.3.2) [33]. At the same time, fatty acid-modified 454 siRNA polyplexes formed positively 
charged particles with diameter of 100-130 nm (TEM images were shown in Figure 3.3.1B) with 
very prominent siRNA binding ability (Figure 3.3.3) [37, 59]. Thus, to optimize the 
physicochemical properties of siRNA polyplexes, 356 was combined with 454 by different 
[targeted PEG oligomer / lipo-oligomer] molar ratios to formulate siRNA as TLP1 formulation. 
For that both oligomers contain terminal cysteines, crosslinkage through disulfide formation is 
assumed to glue together all three components. 
 
Figure 3.3.1. Targeted lipopolyplexes (TLPs) for siRNA delivery. (A) Structures of targeted PEGylated oligomer 
(356) and lipo-oligomers (454, 49 and 229). C: cysteine; K: lysine; Y: tyrosine; PEG: polyethylene glycol; Stp: 
succinoyl-tetraethylene pentamine; OleA: oleic acid; LinA: linolic acid; K( and K[ refer to branchings by α- and ε-
amino modification of lysines. Illustrations and TEM micrographs of (B) targeted PEGylated polyplexes (by folate-
conjugated 356 and siRNA), lipopolyplexes (by oleic acid-modified 454 and siRNA) and (C) TLPs (by co-
formuations of targeted PEGylated oligomer, lipo-oligomer and siRNA). TLP1: 356 + 454; TLP2: 356 + 49; TLP3: 
356 + 229). The TEM imaging was performed in collaboration with Susanne Kempter (Faculty of Physics, Ludwig-
Maximilians-Universität München). 
A 
B 
C 
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Figure 3.3.2. siRNA binding of targeted PEG oligomer (356) at N/P 16 determined by agarose gel shift assay. Free 
siRNA was used as control. 
 
 
Figure 3.3.3. siRNA binding of lipo-oligomers (49, 229, 454) at N/P 16 determined by agarose gel shift assay. Free 
siRNA was used as control. 
 
Table 3.3.1. TLP Formulationsa 
Formulation Targeted PEG Oligomer Lipo-Oligomer 
TLP1 Folate-PEG24-K(Stp4-C)2 (356) C-Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-C (454) TLP2 C-Stp2-[(OleA)2-K]K-Stp2-C (49) 
TLP3 (LinA)2-K-C-Stp3-C (229) 
a The sequence implies from C- terminal to N- terminal. C: cysteine; K: lysine; Y: tyrosine; PEG: polyethylene 
glycol; Stp: succinoyl-tetraethylene pentamine; OleA: oleic acid; LinA: linolic acid; K( and K[ refer to branchings 
by α- and ε-amino modification of lysines. 
 
Moreover, based on this strategy, as shown in Table 3.3.1 and Figure 3.3.1C, lipo-oligomer with 
different motifs such as oleic acid lipo-oligomer (49) or linolic acid lipo-oligomer (229) was 
combined with targeted PEGylated oligomer (356) to prepare TLP2 and TLP3, respectively.  
 
As measured by dynamic light scattering (DLS) (Table 3.3.2), the surface charge of TLP1 at N/P 
16 was dramatically shifted from +16.4 mV (at the ratio of 0%:100% lipo-oligomer) to +2.5 mV 
(at the ratio of 10%:90%) by addition of PEGylated 356. At the ratio of 30%:70%, TLP1 presented 
neutralized zeta potential value and diameter of ~127 nm. Similarly, TLP2 displayed zeta potential 
value of + 0.1 mV and size of ~90 nm (Table 3.3.3) at the ratio of 30%:70%, while TLP3 exhibited 
shielded surface charge (+9.2 mV) and size of ~198 nm at the ratio of 20%:80% (Table 3.3.4). 
Consistent among the TLPs, the morphology of formulations assessed by TEM indicated the TLPs 
were homogeneous spherical nanoparticles with size in a range similar to the DLS measurements 
(Figure 3.3.1C). Additionally, when the ratio approached 50%:50%, probably the 
hydrophilicity/hydrophobicity balance between two classes of oligomers was unstable, the 
increased particle heterogeneity and even agglomeration were observed from the DLS results. 
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To evaluate the siRNA binding ability of TLPs at different mixing ratios, we performed gel shift 
assays (Figure 3.3.4-3.3.6). When the fraction of lipo-oligomers was increased in the TLPs, the 
siRNA binding was greatly potentiated. Notably, complete siRNA binding was observed between 
the ratio of 10%:90% and 30%:70% for TLPs. Compared to 356 polyplexes, the results indicated 
that the presence of the lipo-oligomer in TLP formulations resulted in much improved siRNA 
binding efficiency, while tyrosine-modified 454 in the TLP1 had highest capacity from these 
formulations to stabilize the siRNA polyplexes [37]. In conclusion, by co-formulating two 
functional oligomers, the successful modification of polyplexes was accompanied by distinct 
changes in the physicochemical properties with tunable sizes, surface shielding and improved 
siRNA binding. According to these results, the molar ratios of two oligomers for TLPs were 
optimized (30%:70% for TLP1 and TLP2; 20%:80% for TLP3) for the following in vitro and in 
vivo studies. 
 
Table 3.3.2. Size and zeta potential of TLP1 at N/P 16 by DLS measurements. Folate-PEG24-K(Stp4-C)2 (356) as 
targeted PEG oligomer and C-Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-C (454) as lipo-oligomer were co-formulated according 
to different molar ratios to form siRNA polyplexes.  
[Targeted PEG Oligomer / 
Lipo-oligomer] Molar Ratio Individual N/P Ratios 
Size (nm) PdI Zeta Potential 
(mV) Targeted PEG Oligomer Lipo-oligomer Targeted PEG Oligomer Lipo-oligomer - 100% - 16 114.6±0.92 0.201±0.003 16.4±0.09 10% 90% 2.8 13.2 130.6±0.56 0.137±0.004 2.5±0.24 20% 80% 5.2 10.8 128.7±0.63 0.159±0.004 2±0.17 30% 70% 7.2 8.8 126.6±2.17 0.121±0.007 -0.1±0.18 40% 60% 9 7 1143±205.3 0.96±0.057 0.7±0 50% 50% 10.5 5.5 674±196.9 0.693±0.222 3.7±0.14 60% 40% 11.9 4.1 402±130.6 0.557±0.194 0.2±0.2 70% 30% 13.1 2.9 340±4.5 0.313±0.01 2.6±0.9 80% 20% 14.2 1.8 296±30.8 0.323±0.03 0.03±0.02 90% 10% 15.1 0.9 295±21.7 0.333±0.009 1.5±0.17 
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Table 3.3.3. Size and zeta potential of TLP2 at N/P 16 by DLS measurements. Folate-PEG24-K(Stp4-C)2 (356) as 
targeted PEG oligomer and C-Stp2-[(OleA)2-K]K-Stp2-C (49) as lipo-oligomer were co-formulated according to 
different molar ratios to form siRNA polyplexes. 
[Targeted PEG Oligomer / 
Lipo-oligomer] Molar Ratio Individual N/P Ratios 
Size (nm) PdI Zeta Potential 
(mV) Targeted PEG Oligomer Lipo-oligomer Targeted PEG Oligomer Lipo-oligomer - 100% - 16 90.8±0.4 0.256±0.014 13.6±1.4 10% 90% 2.8 13.2 125.7±1.1 0.126±0.021 17.5±0.6 20% 80% 5.2 10.8 93.5±0.7 0.182±0.003 18.2±0.5 30% 70% 7.2 8.8 90.3±1.5 0.193±0.011 0.1±0.2 40% 60% 9 7 2199±83.5 1±0 1.7±0.1 50% 50% 10.5 5.5 1562±435.4 1±0 4.1±0.5 60% 40% 11.9 4.1 2026±674.2 0.967±0 1±0.3 70% 30% 13.1 2.9 1196±300.1 0.933±0.047 4.3± 80% 20% 14.2 1.8 942±201.6 0.71±0.1 4±0.6 90% 10% 15.1 0.9 445±61.5 0.45±0.04 3.9±0.2 
 
 
 
Table 3.3.4. Size and zeta potential of TLP3 at N/P 16 by DLS measurements. Folate-PEG24-K(Stp4-C)2 (356) as 
targeted PEG oligomer and (LinA)2-K-C-Stp3-C (229) as lipo-oligomer were co-formulated according to different 
molar ratios to form siRNA polyplexes.  
[Targeted PEG Oligomer / 
Lipo-oligomer] Molar 
Ratio Individual N/P Ratios 
Size (nm) PdI Zeta Potential 
(mV) Targeted PEG Oligomer Lipo-oligomer Targeted PEG Oligomer Lipo-oligomer - 100% - 16 224±18.9 0.73±0.14 20.7± 10% 90% 3.8 12.2 183±2.5 0.277±0.04 15±0.5 20% 80% 6.6 9.4 198±4 0.293±0.02 9.2±0.6 30% 70% 8.7 7.3 1046±427.2 0.81±0.142 7.6±1.3 40% 60% 10.4 5.6 2636±1153.2 0.99±0.01 4.7±0.9 50% 50% 11.8 4.2 1096±149.9 0.89±0.08 3±0.6 60% 40% 12.9 3.1 806±135.5 0.66±0.08 2.9±0.2 70% 30% 13.9 2.1 630±122 0.617±0.11 4.2±0.9 80% 20% 14.7 1.3 890±52.2 0.55±0.07 -0.04±0 90% 10% 15.4 0.6 893±76.3 0.561±0.07 5.9±0.9 
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Figure 3.3.4. siRNA binding of TLP1 at N/P 16 determined by agarose gel shift assay. Folate-PEG24-K(Stp4-C)2 
(356) as targeted PEG oligomer and C-Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-C (454) as lipo-oligomer were co-formulated 
according to different [targeted PEG oligomer / lipo-oligomer] molar ratios to form siRNA polyplexes. Free siRNA 
was used as control. Complete siRNA binding was marked in red rectangle. 
 
 
Figure 3.3.5. siRNA binding of TLP2 at N/P 16 determined by agarose gel shift assay. Folate-PEG24-K(Stp4-C)2 
(356) as targeted PEG oligomer and C-Stp2-[(OleA)2-K]K-Stp2-C (49) as lipo-oligomer were co-formulated 
according to different [targeted PEG oligomer / lipo-oligomer] molar ratios to form siRNA polyplexes. Free siRNA 
was used as control. Complete siRNA binding was marked in red rectangle. 
 
 
Figure 3.3.6. siRNA binding of TLP3 at N/P 16 determined by agarose gel shift assay. Folate-PEG24-K(Stp4-C)2 
(356) as targeted PEG oligomer and (LinA)2-K-C-Stp3-C (229) as lipo-oligomer were co-formulated according to 
different [targeted PEG oligomer / lipo-oligomer] molar ratios to form siRNA polyplexes. Free siRNA was used as 
control. Complete siRNA binding was marked in red rectangle. 
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3.3.2 Receptor-mediated internalization and intracellular distribution of TLPs 
To verify targeting capacity of the folate-linked TLPs, fluorescent Cy5-labeled siRNA was 
exploited to study the cellular internalization profile by flow cytometry, and FR-rich tumor cell 
lines as L1210, M109 and KB cells, and FR-deficient cell line as MCF-7 cells [67, 76, 78, 79] 
were subjected for the following experiments.  
 
The cells were treated with TLPs at N/P 16 for 4 h at 37 °C, and then the uptake levels of TLPs 
were analyzed by flow cytometry (Figure 3.3.7A). All the TLP formulations exhibited strong 
cellular internalization in FR-rich cells. The uptake levels for the TLPs in L1210 cells were similar 
(91-93% positive cells), which were higher than the levels in M109 cells (76-81% positive cells). 
On the contrary, all the TLP formulations barely entered FR-deficient MCF-7 cells. For control 
studies, alanine-substituted oligomer 188 and aforestated lipo-oligomers were co-formulated as 
non-targeted lipopolyplexes (NTLPs) (Table 3.3.5). In KB cells, the level of TLP1 (88% positive 
cells) was comparable as 356 polyplexes (91% positive cells), while NTLP1 mediated insufficient 
cellular uptake. In short, these results gave evidence that TLPs were internalized in a FR-specific 
manner, and the folate conjugates were required for association with the target tumor cells. 
 
The crucial question about the membrane association, translocation into cells and the following 
trafficking of TLPs remained obscure. A powerful tool to elucidate the internalization mechanism 
of TLPs is TEM [81], which has been employed to examine the cell entry processes and 
intracellular distribution of various macromolecules and particles [88, 89]. Nevertheless, among 
these, few studies have focused on the targeted delivery of siRNA [76, 90]. To locate the receptor 
in relation to the plasma membrane and cellular organelles, the primary antibodies against FR 
were visualized with Protein G-gold conjugate (6 nm in diameter). To map the siRNA molecules, 
biotinylated siRNA was labeled with neutravidin-gold conjugate (10 nm in diameter). These 
studies were performed during a research visit at Institute of Molecular and Cell Biology, 
University of Tartu. 
 
Table 3.3.5. TLP Formulationsa 
Formulation Targeted PEG Oligomer Lipo-Oligomer 
NTLP1 A-PEG24-K(Stp4-C)2 (188) C-Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-C (454) NTLP2 C-Stp2-[(OleA)2-K]K-Stp2-C (49) 
NTLP3 (LinA)2-K-C-Stp3-C (229) 
a The sequence implies from C- terminal to N- terminal. C: cysteine; K: lysine; Y: tyrosine; PEG: polyethylene 
glycol; Stp: succinoyl-tetraethylene pentamine; OleA: oleic acid; LinA: linolic acid; K( and K[ refer to branchings 
by α- and ε-amino modification of lysines. 
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Figure 3.3.7. Folate receptor (FR)-mediated uptake and intracellular distribution of TLPs. (A) The cellular 
internalization capacity of TLPs was evaluated by comparing the uptake levels of siRNA polyplexes in FR-
overexpressing L1210, M109 & KB vs. FR-deficient MCF-7 cells. siRNA polyplexes were prepared at N/P 16 with 
Cy5-labeled siRNA. The cells were incubated with siRNA polyplexes at 37 °C for 4 h before flow cytometric 
measurements. The amount of Cy5-positive cells was analyzed through excitation of the dye at 635 nm and detection 
of emission at 665/20 nm. (B-F) Immuno-TEM of FR-mediated endocytic pathway for TLP1 in FR-overexpressing 
KB cells. TLP1 was formed at N/P 16 with biotinylated-siRNA tagged with 10 nm neutravidin-gold particles. FR was 
visualized with anti-FR-α antibodies and Protein-G coupled to 6 nm gold particles (green arrowheads in the images 
or red dots in the scheme). The experiments were performed in collaboration with Dr. Kärt Padari (Institute of 
Molecular and Cell Biology, University of Tartu). (B) Association of siRNA polyplexes with the cell surface after 
incubation with siRNA polyplexes for 15 min. (C) The higher-magnification image of blue rectangle in (B) showed 
the association of siRNA polyplexes with FR. (D) The higher-magnification image of red rectangle in (B) showed 
membrane invagination. (E) The higher-magnification image of green rectangle in (D) indicated FR localizing in 
close proximity to siRNA polyplexes. (F) siRNA polyplexes localized inside the vesicular structure after 1 h. 
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As demonstrated in Figure 3.3.7B, after incubating FR-positive KB cells with 10 nm gold label-
containing TLP1 for 15 min, siRNA polyplexes were detected prominently as electron dense 
particles and associated quickly with the cell surface. In the higher-magnification image, siRNA 
polyplexes seemed to be in close contact with the FR (6 nm gold tags indicated by arrowheads in 
Figure 3.3.7C). Subsequently, the colocalization of siRNA polyplexes and the FR (indicated by 
red dots in the scheme of Figure 3.3.7D and arrowheads in the enlarged image as Figure 3.3.7E) 
induced morphological changes in the plasma membrane, leading to the formation of membrane 
invaginations. Later at 1 h, siRNA polyplexes shifted deeper into the cytoplasm, being finally 
fully engulfed by the cell into vesicles (Figure 3.3.7F), which resembled the structures of 
endolysosomal pathway. Besides, NTLP1 were very rarely detected at the cell surface, and this 
correlated well with the inefficient uptake level measured by flow cytometry in KB cells (Figure 
3.3.7A). 
 
 
Figure 3.3.8. Time-lapse confocal laser scanning microscopy (CLSM) for TLP1 transduction in KB cells. TLP1 
was prepared at N/P 16 with AF 647-labeled siRNA (red). The nuclei (blue) were stained with Hoechst 33342. The 
yellow and gray rectangles were enlarged as (B) and (D), respectively. (A) Endosomes (green) were visualized with 
CellLight Late Endosomes-RFP. (B) Lysosomes (green) were marked with CellLight Lysosomes-GFP. The 
experiments were performed in collaboration with Dr. Xueying Liu (Innovation Center of NanoMedicine). 
 
As a next step, the involvement of endo-/lysosomal compartments in the transport of TLPs was 
further differentiated upon a collaborative research visit at Innovation Center of NanoMedicine 
and University of Tokyo. To gain more detailed insights into the dynamics of TLPs, we formulated 
TLP1 with AF 647-labeled siRNA, labeled late endosomes with CellLight Late Endosomes-RFP, 
and lysosomes with CellLight Lysosomes-GFP, and performed time-lapse confocal laser scanning 
microscopy (CLSM) with cultured KB cells. Within 1 h (Figure 3.3.8A), AF 647-labeled siRNA 
(red) polyplexes were gradually associated with late endosomes (green), and the colocalization of 
siRNA and late endosomes was obvious after incubation for 1 and 3 h. As shown in the enlarged 
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image (Figure 3.3.8B), the overlap of two signals suggested that TLP1 was entrapped in late 
endosomes. Between 3 and 4 h, the association with late endosomes diminished; and expectedly, 
at the same time, the colocalization of siRNA polyplexes and lysosomes (green) became excessive 
(Figure 3.3.8C). As shown in Figure 3.3.8D, the majority of siRNA polyplexes were found to be 
inside lysosomes at 4 h.  
 
Hence, these findings validated that TLPs were capable of efficient tumor cell-specific uptake, 
and a particular emphasis is placed on the intracellular distribution of TLPs during FR-mediated 
endocytosis. FR appeared to serve as a docking point for TLPs, and the binding of TLPs to 
receptors shortly induced internalization of siRNA polyplexes within 15 min. Afterwards, at 1−3 
h, late endosomes most often governed the transduction of TLP1, and the vesicles trafficked 
through the endolysosomal pathway experiencing a gradual drop of pH, then siRNA polyplexes 
were finally targeted to lysosomes.  
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3.3.3 siRNA release and reporter gene silencing by TLPs 
As most of TLPs retained their dense packing inside endolysosomal compartments after cellular 
uptake, it is crucial to understand whether the cargo can be released from the endosomal 
entrapments, reach to the cytoplasm and be available for RNAi machinery for mediating gene 
silencing. To shed further light on the siRNA release from TLPs by immuno-TEM, we incubated 
KB cells with TLP1 (N/P 16) for 4 h (Figure 3.3.9). Generally, these TLP1-containing vesicles 
were intact and surrounded by a continuous membrane. Occasionally, some of these vesicles had 
a discontinuous membrane, and the electron density of the vesicle content was undistinguishable 
from that of cytosol (Figure 3.3.9A). Moreover, single (Figure 3.3.9B) or a small cluster (Figure 
3.3.9C) of gold particles were spread apparently free in cytosol, often in the close proximity of 
vesicles with discontinuous membrane. As a key role in the delivery of TLPs, internalized FR 
proteins (arrowheads in Figure 3.3.9B and D) were still associated with siRNA polyplexes.  
 
 
Figure 3.3.9. Morphological changes in TLP1-containing vesicles in FR-overexpressing KB cells at 4 h monitored 
by immuno-TEM. TLP1 was formed at N/P 16 with biotinylated-siRNA tagged with 10 nm neutravidin-gold particles. 
FR was visualized with anti-FR-α antibodies and Protein-G coupled to 6 nm gold particles (green arrowheads in the 
image). Discontinuous membrane of some endosomes resulted in endosomal escape of the siRNA molecules. (A) and 
(C) were accompanied by higher-magnification images, (B) and (D), respectively. The experiments were performed 
in collaboration with Dr. Kärt Padari (Institute of Molecular and Cell Biology, University of Tartu). 
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Figure 3.3.10. Reconstructed KB cell showing the distribution of siRNA, late endosomes and lysosomes based on 
CLSM. KB cells were incubated with TLP1 (N/P 16) containing AF 647-labeled siRNA (red) for 4 h. Late 
endosomes (blue) were visualized with CellLight Late Endosomes-RFP, and lysosomes (green) were marked with 
CellLight Lysosomes-GFP. The experiments were performed in collaboration with Dr. Xueying Liu (Innovation 
Center of NanoMedicine). 
 
 
 
Figure 3.3.11. The scheme interpreting the distribution of siRNA, late endosomes and lysosomes in reconstructed 
KB cell using CLSM. 
 
In an attempt to confirm the dislocation of siRNA from endolysosomal compartments, the results 
obtained by TEM were complemented by analogous experiments with CLSM. TLP1 was 
complexed with AF 647-labeled siRNA at N/P 16, and KB cells were stained with CellLight Late 
Endosomes-RFP and CellLight Lysosomes-GFP. To avoid misleading interpretation based on 
spatial limitations, 3D reconstruction of serial images from single cell was utilized (Figure 3.3.10 
and 3.3.11). As shown in Figure 3.3.10, lysosomes (green) were dominant, and late endosomes 
(blue) were scarcely distributed in the cell. Similarly, siRNA molecules (red) were largely 
overlapped with late endosomes (purple) or lysosomes (yellow). Notably, although at low 
frequency, escaping siRNA molecules were detectable (yellow arrowheads in Figure 3.3.10), 
suggesting TLP1 managed to deliver siRNA into cytosol. 
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Figure 3.3.12. Gene silencing efficiency of TLPs in KB cells expressing eGFPLuc fusion protein (KB/eGFPLuc cells) 
measured by luminometer. The siRNA polyplexes were prepared at N/P 16 with different siRNA sequences: eGFP-
targeted siRNA (siGFP) and control siRNA (siCtrl). After incubation of TLPs for 45 min, the luciferase expression 
was analyzed at 48 h, and presented as percentage in comparison to untreated control cells. 
 
We next planned to estimate the ability of TLP formulations to induce target gene silencing in the 
cancer cell culture models. For this, we formulated siRNA targeting eGFP (siGFP) or control 
siRNA (siCtrl) within the different TLP formulations and carried out the transfections in the 
KB/eGFPLuc cells, which are stably expressing eGFP-Luciferase (eGFPLuc) fusion protein, and 
evaluated target gene silencing via luciferase activity by luminometric analysis. As shown in 
Figure 3.3.12, all the TLP formulations containing siGFP at N/P 16 mediated significant gene 
silencing efficiency in KB/eGFPLuc cells, as 73-88% of luciferase activity was downregulated. 
This effect was superior to the parent 356 polyplexes (55%). Among these TLP formulations, the 
most efficient gene silencing activity was achieved by TLP1 (88%). At the same time, polyplexes 
with siCtrl did not induce any unspecific gene silencing. Furthermore, non-targeted NTLPs 
formulations failed to reduce the reporter gene expression, highlighting that TLPs were taken up 
and able to invoke RNAi in the target cells by a specific manner. Very importantly, the parent 
oligomer 356 had limited ability for endosomal escape, and for robust pharmacological activity, 
it required the presence of the endosomolytic Inf7 peptide modification on siRNA [33]. As 
indicated by the studies above, the novel formulation strategy enabled us to overcome this 
limitation and achieve very efficient gene knockdowns with simply regular siRNA (without the 
need for additional endosmolytic modification).  
 
To conclude, TEM and CLSM demonstrated the intracellular mode of trafficking of the TLPs and 
their ability to release siRNA from endosomes to cytosol (i.e. the site-of-action of siRNA). 
Furthermore, the gene silencing assay confirmed that TLPs allowed the siRNA to be released from 
polyplexes after FR-mediated endocytosis, and showed remarkable target gene silencing effect.  
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3.3.4 Receptor-dependent antitumoral activity by EG5 gene silencing 
As aforementioned, TLPs mediated impressive functional gene silencing in vitro, and hence we 
next sought to investigate, whether by siRNA against EG5 (siEG5) we could achieve cell-targeted 
cytotoxicity in FR-expressing tumor cells. We formulated TLPs with siEG5 and treated both FR-
positive KB cells and FR-negative MCF-7 cells for 45 min.  
 
 
Figure 3.3.13. Treatments of TLPs containing EG5-targeted siRNA (siEG5) or control siRNA (siCtrl) at N/P 16. (A) 
Metabolic activity of FR-positive KB and FR-negative MCF-7 cells at 48 h after treatment with TLPs. (B) KB cells 
treated with TLPs observed by DAPI staining under the fluorescent microscope. The mitotic blockade that was 
induced by EG5 knockdown caused "aster formation" of nuclear DNA (yellow arrows). The scale bars represent 10 
μm. (C) mRNA level of EG5 gene measured by qRT-PCR at 48 h after transfection of TLPs in FR-positive KB and 
L1210 cells. GAPDH was used as housekeeping gene. 
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After incubation for 48 h, a metabolic activity assay was used for assigning cell viability upon the 
treatments with the formulations, which reflected that all the siEG5 TLP formulations initiated 
effective cell killing in KB cells (Figure 3.3.13A).  Besides, siCtrl TLPs did not affect cell viability 
in KB cells, indicating EG5-mediated effect was specific. Also, experiments in FR-negative MCF-
7 cells confirmed that EG5-containing TLP formulations did not have any cytotoxic effect on non-
target cells, indicating that uptake and cytotoxicity of the formulation was driven by the folate-FR 
interaction (Figure 3.3.13A). Moreover, siEG5-mediated cytotoxicity by EG5 was also confirmed 
in another FR-overexpressing cell line M109 (Figure 3.3.14). Moreover, it has been demonstrated 
that EG5 protein downregulation by RNAi leads to a monopolar spindle formation and arrest of 
cells in prometaphase with a phenotype as aster formation of nuclear DNA [53, 91]. After 
incubation with siEG5 TLPs, Figure 3.3.13B illustrated such typical mitotic asters (indicated by 
yellow arrows) in KB cells by DAPI staining. As expected, no aster formation was observed in 
case of siCtrl TLPs treatments. 
 
EG5-specific gene silencing at mRNA level was further examined by qRT-PCR in FR-expressing 
KB and L1210 cells. As seen in Figure 3.3.13C, treatments with all siEG5 TLPs triggered 
pronounced degradation of EG5 mRNA expression levels in both cell lines. Moreover, siCtrl 
treatment remained on bar with untreated group, indicating the specificity of the EG5 knockdown 
without off-target effect. It is of notice that TLP2 and TLP3 had very similar gene silencing 
activity by qRT-PCR, in line with the preceding silencing experiments in the eGFPLuc assay 
(Figure 3.3.12). Interestingly, in both silencing models, TLP1 was significantly more potent than 
the rest of formulations (92% in KB cells; 85% in L1210 cells).  
 
Figure 3.3.14. Metabolic activity of FR-postivie M109 cells after treatments of TLP containing EG5-
targeted siRNA (siEG5) or control siRNA (siCtrl) at N/P 16 at 48 h.  
 
These results provided clear evidence that folate-conjugated TLPs enabled efficient silencing of 
EG5 expression at mRNA level, followed by mitotic blockade and finally cell death, and these 
effects were mediated by the presence of the FR on the cancer cells. Whereas, further studies were 
required to discern the potential factors for the different gene silencing potencies of different TLPs. 
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3.3.5 siRNA release kinetics and stability in cells 
Although all the TLPs induced comparably efficient cellular uptake in FR-expressing cells (Figure 
3.3.7A), gene silencing ability for different TLPs varied for some reason (Figure 3.3.12 and 
3.3.13C). To explore the underlying mechanisms, with a focus on molecular pharmacokinetics, 
we examined the translocation of siRNA from endosomes to cytosol after transfection to estimate 
endosomal escaping capability profile of each formulation. The intracellular distribution of AF 
647-labeled siRNA polyplexes was analyzed by co-staining of late endosomes and lysosomes 
using LysoTracker Green in KB cells with CLSM. As presented in Figure 3.3.15A, colocalization 
(yellow) of AF 647-labeled siRNA (red) with late endosomes and lysosomes (green) was 
monitored at 2 and 4 h. As previously shown in Figure 3.3.8, the TLP-containing vesicles were 
actively shifted from late endosomes to lysosomes between 3 h and 4 h after transfection, where 
TLPs experienced gradual acidification.  
 
A 
 
B 
 
Figure 3.3.15. Colocalization of siRNA polyplexes with late endosomes and lysosomes was presented by CLSM. (A) 
Intracellular distribution of AF 647-labeled siRNA (red) polyplexes in KB cells at 2 and 4 h after transfection for 45 
min. Late endosomes and lysosomes were stained with LysoTracker Green (green). Nuclei were stained with DAPI 
(blue). (B) After tranfection for 45 min, colocalization ratios of AF 647-labeled siRNA with late endosomes and 
lysosomes were calculated using ZEN 2.1 software at 2 and 4 h. The experiments were performed in collaboration 
with Dr. Xueying Liu (Innovation Center of NanoMedicine). 
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Furthermore, we observed a significant decrease in the colocalization ratios of all the TLPs in late 
endosomes and lysosomes (green) at 4 h after transfection (Figure 3.3.15B), indicating the onset 
of siRNA release from endosomes began during acidification of endolysosomal structures. Co-
localization ratios of TLP1 were significantly higher than those of TLP2 and TLP3 at both 2 h 
and 4 h. This suggested that TLP2 and TLP3 had earlier endosomal escape capacity than TLP1. 
On the other hand, it seemed that sustained release of siRNA from endosomes to cytosol caused 
the enhanced gene silencing effect of TLP1, which corresponded with the results measured 48 h 
after transfection of TLPs (Figure 3.3.12 and 3.3.13C). As mentioned in literature, the decrease in 
intravesicular pH takes time along the endolysosomal pathway from pH 6.0−6.5 in early 
endosomes to pH 4.5−5.5 in late endosomes and lysosomes [92, 93], escaping of siRNA from 
vesicular compartments in response to dropping intravesicular pH for different TLP formulations 
may occur in different time courses. 
 
In light of effective gene silencing effect, intracellular siRNA stability must also be taken into 
consideration. Through fluorescence resonance energy transfer (FRET) analysis, we aimed to 
track the stability and degradation of siRNA delivered by different TLP formulations in FR-
expressing KB and L1210 cells. For this purpose, Cy5/TAMRA double-labeled siRNA was 
utilized: on the sense strand of siRNA, Cy5 was conjugated at the 5' end, and TAMRA was at 3’ 
end. After Cy5/TAMRA double-labeled siRNA transfection for 1, 4, and 48 h, FRET intensity of 
cells was analyzed with flow cytometry by exciting the cells with a 488 nm laser and monitoring 
the fluorescence emission through a 660/20 nm filter. The mean FRET intensity of each TLP 
formulation was calculated by using FACSDiva software (Figure 3.3.16).  
 
 
Figure 3.3.16. Intracellular fluorescence resonance energy transfer (FRET) signals were analyzed by flow cytometry 
at 1, 4 and 24 h after Cy5/TAMRA double-labeled siRNA transfection for 45 min in KB and L1210 cells. The samples 
were excited with a 488 nm laser, and their emission was monitored by using a 660/20 filter. The experiments were 
in collaboration with Naoto Yoshinaga (Department of Bioengineering, University of Tokyo). 
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Because FRET efficiency falls off as 1/R6, observation of FRET is typically limited to 
donor/acceptor distances of about 10 nm [94], and, therefore, FRET is only measurable when 
siRNA duplexes remain intact inside cells, otherwise the degradation of siRNA results in the loss 
of FRET. In KB cells, all the TLPs maintained high FRET intensity at 1 h. At 4 h, FRET intensity 
of TLP1 dropped only slightly by 7%, in contrast to TLP2 (loss by 39%) and TLP3 (loss by 24%), 
showing that siRNA remained intact in case of TLP1 formulation. Although FRET intensity of 
TLPs decreased up to 90-95% within 24 h, notably, FRET intensity of TLP1 remained 2-fold 
higher compared to TLP2 and TLP3. Similarly, in L1210 cells, FRET intensity of TLP1 was 
higher than those of TLP2 and TLP3 after incubation for 1 h, and similar trend was found at 24 h.  
 
Additional proof of siRNA stability was obtained by CLSM in cultured KB cells transfected with 
Cy5 (red) and TAMRA (green) double-labeled siRNA. Lysosomes were labeled with CellLight 
Lysosomes-GFP (blue). As demonstrated by the representative examples in Figure 3.3.17, TLP1 
showed extensive colocalization of the two fluorophores (yellow), i.e. intact siRNA, after 
incubating the cells for 1 h. Red or green pixels indicating the degraded siRNA molecules were 
also observed. Impressively, after 24 h, despite most of siRNA sequences were degraded by 
lysosomes, intact siRNA was still detectable. On the contrary, without 454, 356 protected only 
few intact siRNA molecules at 1 h, and none at 24 h.  
 
Figure 3.3.17. FRET imaging of Cy5 (red)/TAMRA (green) double-labeled siRNA at 1 and 24 h after transfection 
for 45 min in KB cells by CLSM. Colocalization of the two fluorophores (yellow) indicated intact siRNA. Lysosomes 
were labeled with CellLight Lysosome-GFP (blue). The scale bars represent 10 μm. The experiments were in 
collaboration with Dr. Xueying Liu (Innovation Center of NanoMedicine). 
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To conclude, on the condition that there was no significant difference for cellular internalization 
levels for TLPs, TLP1 is hypothesized to unload siRNA in a rather sustained manner based on the 
delayed shift in colocalization with late endosomes/lysosomes. Furthermore, TLP1 exhibited 
superior ability to confer the protection and stability of siRNA compared to the other formulation, 
as measured by a distance-dependent FRET-based approach. Since TLP2 and TLP3 did not show 
significant difference regarding endosomal escaping capability, siRNA stability and biological 
activity, it appeared that the modification of tyrosines to the fatty acid-based TLP1, which provides 
further stability to the polyplex, was essential for the increased activity of the formulations. 
 
3.3.6 Tumoral delivery and gene silencing upon systemic administration 
From the drug delivery standpoint, systemic delivery of siRNA poses a great challenge, since 
siRNA is readily degraded by serum endonucleases and is easily eliminated by glomerular 
filtration with a short plasma half-life of <10 min [95]. In order to understand whether TLPs could 
improve the distribution profile of siRNA, folate-conjugated TLP1, the most potent formulation 
in vitro with favorable size and surface charge, was selected for the further in vivo studies. The 
two single oligomer components of TLP1, i.e. PEGylated folate-equipped oligomer (356) and 
tyrosine-based oleic acid oligomer (454), were used for comparison. Non-targeted analogue 
NTLP1 and naked siRNA were also exploited as controls. FR-expressing L1210 tumor cells were 
implanted subcutaneously in nude mice. We formulated different Cy7-labeled siRNA (at the dose 
of 50 µg of siRNA) polyplexes at N/P 16, and administered these siRNA polyplexes intravenously 
(i.v.). The biodistribution of Cy7-labeled siRNA measured by near infrared (NIR) fluorescence 
imaging was demonstrated in Figure 3.3.18A. As Cy7-labeled siRNA spread throughout the 
whole body along with the blood circulation immediately after injection, Cy7 signal of naked 
siRNA lasted for merely 30 min. PEGylated folate-equipped oligomer 356 formed nanoparticles 
with a diameter of ~6 nm, approached the tumor site with small fraction of Cy7 signal at 15 min, 
and transiently disappeared after 30 min. Meanwhile, tyrosine-based 454 (100-130 nm in diameter) 
significantly improved the systemic retention of siRNA >4-fold over naked siRNA and 356. For 
that the volume of blood circulates through the tumor is usually far less than that of the arteries, 
only the nanoparticles that are not rapidly cleared from the circulation will have a chance to 
encounter the leaky tumor vasculature for targeting [96]. Accordingly, TLP1, as an optimized co-
formulation of 356 and 454, has not only mediated comparably prolonged systemic retention as 
454, more advantageously, but also enhanced tumoral siRNA delivery within 2 h. Notably, Cy7 
signal was detectable in harvested tumors only from TLP1-treated animals at 2 h, while there was 
no Cy7 signal in the rest of groups including folate-linked 356 (Figure 3.3.18B). As non-targeted 
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control, NTLP1 resulted in similar circulation profile as TLP1 but siRNA barely reached the tumor 
site, thus it revealed an explicit difference for the functionality of folate ligands.  
 
 
Figure 3.3.18. Biodistribution of TLP1 at N/P 16 in NMRI-nude mice bearing L1210 tumors via i.v. administration 
determined by NIR fluorescence bioimaging. 50 μg of Cy7-labeled siRNA was foumulated with TLP1, NTLP1, 
PEGylated folate-conjugated oligomer 356, or tyrosine-conjugated oleic acid oligomer 454 as carrier. Experiments 
were performed with 3-4 animals per group; a representative animal of each group is shown. (A) Time-dependent 
tumoral retention of siRNA polyplexes over 24 h. Lateral views of animals were shown to present the tumor sites 
(dotted circles). (B) Tumors harvested 30 min and 2 h after injection of siRNA polyplexes. The experiments were 
performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-
Universität München). 
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Upon systemic administration of siRNA polyplexes, the elimination profiles were presented in 
Figure 3.3.19. It is known that despite the formulation can be modified to prolong blood 
circulation, but non-specific distribution in the highly perfused organs including liver, kidneys 
and lung has thus far been inevitable [86]. In addition, several in vivo studies have reported that 
kidneys are prevailing in siRNA elimination [95], and the pore size of the glomerular filtration 
barrier is roughly 8 nm [97]. Not surprisingly, due to small particle size of 356 (6 nm in diameter), 
Cy7-siRNA immediately passed through glomeruli and was excreted into the urinary bladder 
within 1 h. For the purpose of circumventing rapid renal clearance, siRNA polyplexes should have 
a particle size of about 50-300 nm [98]. Interestingly, TLP1, with a diameter of 127 nm, seemed 
to take advantage of it component 454 to greatly reduce kidney uptake and increase systemic 
retention of siRNA for 4 h. Identical impact of 454 on the distribution profile can be also found 
in case of NTLP1.  
 
 
Figure 3.3.19. Biodistribution of TLP1 at N/P 16 in NMRI-nude mice bearing L1210 tumors via i.v. administration 
determined by NIR fluorescence bioimaging. 50 μg of Cy7-labeled siRNA was foumulated with TLP1, NTLP1, 
PEGylated folate-conjugated oligomer 356, or tyrosine-conjugated oleic acid oligomer 454 as carrier. Experiments 
were performed with 3-4 animals per group; a representative animal of each group is shown. (A) Distribution and 
elimination of siRNA polyplexes over 24 h. Animals were presented in the ventral view. (B) Tumors and organs 
harvested 1 h and 24 h after injection of siRNA polyplexes. The experiments were in collaboration with Eva Kessel 
(Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München). 
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After clarifying that FR-specific TLP1 successfully delivered siRNA to the tumor via i.v. injection, 
we sought to validate the functional gene silencing of TLP1 in vivo. For this aim, we formulated 
TLP1 with siEG5 or siCtrl (50 µg of siRNA), and administered these siRNA polyplexes i.v. in the 
L1210 tumor-bearing mice twice. 24 h after the last treatment, we harvested the tumor, extracted 
RNA and measured the EG5 mRNA levels by qRT-PCR (Figure 3.3.20A). Compared to untreated 
controls, the siEG5 TLP1 induced significant downregulation of EG5 expression by 65%. 
Importantly, siCtrl TLP1 showed negligible effects on mRNA level of EG5 as compared with 
untreated tumors. 
A 
 
B 
 
Figure 3.3.20. Gene silencing effect of TLP1 at N/P 16 in NMRI-nude mice bearing L1210 tumors via i.v. 
administration. (A) mRNA level of EG5 gene after two-fold i.v. injections of TLP1 with 50 μg of siEG5 or siCtrl. 
Experiments were performed with 5 animals per group. (B) Body weight development over treatment period. The i.v. 
injections were performed on day 12 and 13 as indicated by blue arrows. The body weight curves of TCP-treated 
animals were compared to that of untreated animals over the same time after tumor inoculation. Experiments were 
performed with 5 animals per group. The experiments were in collaboration with Eva Kessel (Dr. med. vet. study, 
Department of Pharmacy, Ludwig-Maximilians-Universität München). 
 
Systemic circulation of siRNA polyplexes might also lead to exposure to non-target tissues which 
might cause potential side effects; we therefore monitored the body weights and carried out blood 
biochemistry examinations to help us realize the biocompatibility of TLP1. As shown in Figure 
3.3.20B, the body weight curves indicated that the treatments were well-tolerated compared to 
untreated controls. The blood samples were collected 24 h after the treatments to determine four 
relevant clinical biochemistry parameters (ALT, AST, BUN and creatinine). Increased liver 
enzymes (ALT and AST) would indicate formulation-associated liver damage or acute hepatitis, 
while elevated BUN or creatinine would be related to renal malfunctions. As presented in Table 
3.3.6, in the treatment groups, the levels of ALT and AST were in a range equivalent to the 
untreated control group. In context of creatinine and BUN, there was no significant difference, 
either. 
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Table 3.3.6. Clinical biochemistry parameters (ALT, AST, BUN and creatinine). Plasma was obtained from the 
treated animals 24 h after the second injection (n = 5) compared to untreated tumor-bearing mice (n = 3) that were 
euthanized on the same day.  
  ALT (U/L) AST (U/L) Creatinine (mg/dL) BUN (mg/dL) 
TLP1 + siEG5 39 ± 2 120 ± 31 0.09 ± 0.01 40 ± 8 
TLP1 + siCtrl 57.4 ± 25 130 ± 46 0.09 ± 0.01 39 ± 7 
Untreated 46 ± 15 113 ± 23 0.07 ± 0.01 38 ± 7 
 
To draw a conclusion, these encouraging results suggested that TLP1 delivered siRNA to the 
tumor within 2 h via i.v. injection, inducing specific RNAi-mediated degradation of EG5 mRNA 
in the tumor tissue. Moreover, no indication for potential side effects was given based on the body 
weight analysis and in clinical chemistry measurements from the blood. 
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4 Discussion 
4.1 Oligoglutamyl-MTX-conjugated nanoplexes 
One effective approach in cancer therapy is the use of a combination therapy with different 
therapeutic agents, allowing to tackle the disease from different angles. While such approaches 
with standard chemotherapeutic drugs are effectual and usually decrease the likelihood for 
chemoresistance, they still lack specificity and are associated with considerable toxicity. Novel 
gene therapeutic tools, such as RNAi, offer very interesting alternatives for modulating such 
therapy as they process sequence-specific gene silencing implicated in cell division, and 
importantly, may be used in combination with classical chemotherapeutic drugs. Another crucial 
aspect in cancer therapy is to be able to overcome or significantly decrease the side effects and 
associated toxicities of the therapeutics. The aim in this work was to combine two different 
antitumoral agents (the chemical DHFR inhibitor MTX and the mitosis-inhibiting EG5 siRNA) 
into one nanoparticle drug. Therein we took advantage of the bifunctional MTX which has been 
recently shown to possess potential as both cytotoxic drug and targeting ligand in a cancer 
combination therapy approach for the co-delivery of cytotoxic poly(I:C) [50]. As part of a 
multifunctional nanoplex, MTX was also supposed to facilitate targeted delivery of antitumoral 
EG5 siRNA to the tumor cells. 
 
The structure of the used oligoaminoamides is based on analogous folate-containing two-arm 
branched oligomers with receptor-targeted gene silencing capacity in vitro and in vivo [33]. The 
artificial oligoamino acid succinoyl tetraethylene pentamine (Stp) together with natural amino 
acids (lysine, cysteine) serve as siRNA binding carriers, a PEG chain provides nanoplex shielding. 
In the current work, MTX derivatives acted as targeting ligand. As measured by FCS (Table 3.1.2), 
AFM (Figure 3.1.4) and TEM (Figure 3.1.5), these MTX conjugates electrostatically complexed 
siRNA and formed compact homogeneous spherical nanoparticles with hydrodynamic diameter 
of ~6 nm. The branched two-arm structure containing several Stp units provided the positive 
charge for siRNA binding, and two cysteines further stabilized the polyplex via disulfide 
crosslinking. As a result of the PEGylation, the surface charges of polyplexes were almost 
neutralized, which not only prevented aggregation, but also shielded the particles from unspecific 
cationic association and allowed for specifically presenting the targeting ligand to the cells. 
Considering that these polyplexes were only ~1.3 fold larger than free siRNA, it indicated that 
these PEGylated glutamyl-MTX conjugates were associated with single siRNA in a 
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monomolecular fashion, in line with the previous results with the PEGylated folate-conjugated 
oligomer 356 [33]. 
 
The cellular uptake studies demonstrated that the MTX oligomer conjugates were taken up into 
cells in a FR-specific fashion, as the polyplexes were avidly binding to FR-expressing KB cells 
while only negligible staining was seen in FR-negative A549 cells. Furthermore, in the 
competition assay, binding of polyplexes was blocked by preincubation with excess free folate or 
MTX. We also verified FR-specific targeting effect of MTX conjugates by a series of functional 
siRNA-mediated gene silencing assays in comparison between KB and FR-deficient MCF-7 cell 
lines. In the literature, the relationship between tumor response to MTX and FR expression has 
been extensively investigated. First, KB cell sublines with below-wildtype FR expression show 
resistance for MTX [99], while the cell lines lacking functional RFC are also commonly resistant 
to MTX [100]. Second, the IC50 of MTX for the cells co-expressing RFC after transfection with 
FR-α is the same as for the wild type [101], whereas MTX is active in cell lines that are RFC-
deficient but overexpress FR-α [102, 103]. In addition, it has been reported that transfection of 
MCF-7 cells which do not express FR with FR cDNA increases MTX uptake and cytotoxicity 
[78]. It has been also shown that FR-mediated transport of MTX is highly energy-requiring and 
ceases rapidly when energy metabolism is blocked [104]. Moreover, MTX has been coupled to 
many natural and synthetic carriers, resulting in either amide or ester bond formation. The use of 
either conjugation or encapsulation approaches could change the cellular transport characteristics, 
pharmacokinetics and pharmacodynamics of the parent drug, resulting in increased or decreased 
cytotoxicity, along with altered in vivo distribution [105, 106]. For example, the uptake of a 
PAMAM dendrimers covalently conjugated with MTX is taking place in a FR-dependent manner 
in KB cells [71], and a polyvalent dendrimer-MTX conjugate is not toxic to FR-negative cells 
[107]. More importantly, polyglutamylation of the MTX at its γ-carboxylic acid is known to 
prevent transport of MTX across the membrane by RFC [108], and the oxidized pteridine ring as 
well as a glutamate tail are required for the greatest FR-α affinity [109]. In contrast to free MTX 
which could also enter the cell through the RFC, our findings confirmed a FR-specific uptake of 
MTX conjugated siRNA polyplexes. 
 
Following FR-mediated internalization, the siRNA-linked endosomolytic Inf7 peptide is 
supposed to enhance endosomal escape into the cytosol, where the crosslinking disulfide bridges 
of the oligomer coat are thought to be cleaved within the reductive intracellular environment in 
order to release the siRNA and glutamylated MTX conjugates. In KB/eGFPLuc cells, all of these 
 79 
 
Discussion 
polyplexes (638-642) mediated successful gene silencing potency with Inf7-modified siGFP 
(Figure 3.1.9). Among the MTX conjugates, 640 exhibited the best performance, and higher N/P 
ratios further enhanced the transfection efficiency. Lack of Inf7 peptide in the siRNA construct 
reduced the gene silencing potency (Figure 3.1.10). Consistent with prior work with free oligomer 
conjugates and poly(I:C) complexes [50], oligo-glutamyl MTX conjugates (639, 640 and 641) 
were found to be more cytotoxic than free MTX (Figure 3.1.12). One explanation is that 
conjugated MTX could be internalized in higher quantities than free MTX in this model. Moreover, 
the glutamylation degree of MTX conjugates correlates to DHFR inhibition potency [50], which 
results in suppression of downstream effects on thymidylate and purine synthesis, and might be 
responsible for enhanced potency. In the experiments directly comparing the EG5 siRNA-
mediated cytotoxicity in KB cells, it showed that in general MTX conjugates elicited considerably 
higher cytotoxicity levels compared to the folate analogue 356. Also, the inhibitory efficacy of the 
conjugates seemed to be related to the increasing degree of polyglutamylation from 638 (MTX-
Stp) to 641 (6E-MTX-Stp). The tetraglutamylated 640 and hexaglutamylated 641 siRNA 
polyplexes induced the most significant cytotoxicity, therefore this might indicate that the degree 
of polyglutamylation not only increased the MTX cytotoxicity but also potentiated the siEG5-
dependent cytotoxicity in KB cells (Figure 3.1.12). 
 
In the present study, upon i.t. administration of MTX-based 640 polyplexes showed significantly 
increased intratumoral retention time and achieved levels comparable or even exceeding the 
folate-based 356 polyplexes, and the remaining Cy7 signal in the 640-treated tumor was higher 
than 356-treated tumor after 168 h (Figure 3.1.15). In vivo distribution of siRNA polyplexes is 
dependent on (1) the physicochemical properties of the carrier, (2) the nature of the siRNA, and 
(3) the anatomy and physiology of the drug distribution site. Once the siRNA polyplexes have 
been injected into the interstitial space in the tumor, they have to avoid interactions with the 
extracellular matrix (including collagens, proteoglycans, hyaluronic acid, fibronectin, and other 
glycoproteins) such as binding, dissociation, or aggregation. MTX-conjugated 640, folate-
conjugated 356 and alanine-substituted 188 polyplexes were all PEGylated, which decreased the 
surface charge close to neutrality, and consequently avoided associating with these components. 
PEG molecules as hydrophilic domains were also vital for particle stabilization to prevent 
aggregation of polyplexes. Moreover, the particle size is known to be intrinsically related to the 
rate of clearance from the blood circulation. Nanosized 356 or 640 polyplexes are as small as 
abundant pores present in normal tissue endothelium [110],  allowing good tissue penetration and 
slower removal from the circulation compared to free siRNA. Furthermore, considering that 
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the interstitial or extracellular pH in solid tumors is generally acidic, and the FR-α transport route 
has an affinity for folate that is comparable to that of MTX at low pH [111], such environment is 
beneficial for MTX conjugate 640 to compete with endogenous folate (N-5-
methyltetrahydrofolate) for receptor binding and the following cellular internalization in KB 
xenograft tumors. 
 
This study developed a molecule-defined nanoplex with bifunctional MTX ligand for effective 
intratumoral delivery of siRNA, which represents a challenging hurdle for the widespread 
application of RNAi in cancer research and therapy. First, the tetraglutamylated MTX of 640 
showed greater in vivo KB tumor inhibition compared to equivalent free MTX (Figure 3.1.20A), 
validating the potentiated efficacy resulting from the degree of polyglutamylation. Second, 640 
siRNA polyplexes (with siEG5-Inf7 or siCtrl-Inf7) led to significantly improved tumor 
suppression over free 640 (Figure 3.1.17A), which was expected to diffuse quickly after the 
administration because free 640 in the absence of siRNA failed to form nanoparticles. In addition, 
the endosomolytic Inf7 peptide contained within the siRNA polyplexes may facilitate the cytosolic 
delivery of polyplex-linked MTX molecules, enhancing their toxicity. In this respect, the co-
delivery of siRNA/drug combinations by chemical or physical linkage into the same nanoparticle 
may present a therapeutic advantage in cancer treatment [112]. Encouragingly, the dual 
antitumoral mechanisms consisting of MTX-conjugated 640 and EG5 siRNA have shown 
enhanced antitumoral potency with 50% of recurrence-free survival (Figure 3.1.17C). 
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4.2 Targeted combinatorial polyplexes (TCPs) 
By co-formulation strategy, TCP formulations presented different particle sizes and reduced 
surface charges as measured by DLS. These siRNA polyplexes were uniform compact 
nanoparticles without aggregates observed by TEM (Figure 3.2.3A), and siRNA complexation 
was verified by agarose gel shift assay (Figure 3.2.3B). 
 
Measured by flow cytometry, the folate-based TCPs bound to FR-expressing L1210 and M109 
cells in a receptor-specific pattern (Figure 3.2.4A). Characterization of the cellular uptake of TCPs 
in FR-positive KB cells by immuno-TEM further revealed the interaction of the siRNA polyplexes 
with FR at the plasma membrane and induction of their internalization via FR-mediated 
endocytosis. After internalization, the siRNA polyplexes mainly distributed in endocytic vesicles, 
where the FR remained in contact with TCPs and retained the colocalization. Upon longer 
incubation time, the membrane of TCP-containing vesicles became unstable and discontinuous, 
the tight clusters of siRNA polyplexes started to dissociate. Consequently, the occasional escape 
from endosomes and single TCP distribution to the cytosol was noted (Figure 3.2.4).  
 
Endosomal entrapment is widely recognized as the main obstacle that limits the application of 
therapeutic nanocomplexes, whose target is in the cytoplasm or in the nucleus. It is of notice that 
oligoaminoamides were designed to act as PEI-like proton sponge motifs; by becoming 
increasingly protonated during acidification of endolysosomal structures, and to cause osmotic 
swelling of endosomes and release of the siRNA molecules upon vesicle rupture [42, 113, 114]. 
Published studies in the field of FR-targeted therapeutics have mainly focused on their role in 
bioactivity, but exact cellular trafficking has not been well studied so far. To our knowledge, this 
is the first time when immuno-TEM was applied to clarify the interactions of siRNA polyplexes 
and FR. 
 
As shown in Figure 3.2.5, Inf7 peptide is necessary for efficient transfection of siRNA for TCPs 
and 356. Besides, recently we verified that the uptake of 100-200 nm FR-targeted polyplexes 
could be blocked completely by excess free folate, while the agglomerated large particles (>200 
nm) might partially undergo receptor-independent uptake and gene silencing [115]. The luciferase 
activity in KB/eGFPLuc cells treated with controls, including siCtrl polyplexes and siCtrl-Inf7 
polyplexes were similar to untreated cells, suggesting that there’s no intrinsic cytotoxicity of TCPs. 
Taken together, the gene silencing assay further showed that folate-containing TCPs allowed the 
Inf7-modifed siRNA polyplexes to access the cytosol, and showed not only gene-specific 
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silencing ability but also lack of cytotoxicity mediated by TCPs in KB/eGFPLuc cells.  
 
After systemic administration, there are many ways by which siRNA carriers leave the 
bloodstream, including redistribution into the liver, spleen, kidneys and lung, nonspecific 
distribution has thus far been unavoidable; however, entering kidneys is the most common 
pathway [86]. The glomeruli in kidneys work as a filtration barrier that removes water and small 
molecules as urine while larger molecules are retained in the blood stream [116]. For mice, the 
excretion through kidneys typically occurs for molecules less than 30 kDa in size [117]; the 
molecular weight of naked siRNA is about 13 kDa [6], which readily passes glomerular 
fenestration and accumulates in urine. Aimed to avoid immediate glomerular filtration, we 
increased the particle size by introducing 3-arm Stp oligomers with larger size, and showed 
preliminary improvement on circulation time and therefore increased chance for TCPs to 
extravagate into the FR-expressing tumor.  
 
In addition, to overcome steric hindrance surrounding the FR on the cell surface [118], a PEG 
linker was utilized to conjugate the oligomer to folate. PEGylation can minimize the protein 
binding and possibly attributes to the low clearance by the reticuloendothelial system or 
accumulation in related organs especially the liver [119], as extremely low Cy7 signal in liver and 
spleen was detected (Figure 3.2.7D). On the other hand, the hydrophilic nature of PEG might 
facilitate the renal excretion of TCPs [120]. 
 
Therefore, encouragingly, these results suggested that siEG5-Inf7 TCP1 successfully reached the 
target tissue via i.v. injection, rendering gene silencing in the tumor. It is considered that low 
toxicity is as important as functional activity; if siRNA delivery provoked unacceptable toxicity 
on either a cellular or systemic level, even the most effective siRNA delivery system would be 
vainness [121]. Thus it is important that the blood analysis gave no indication for toxicity affecting 
vital organs like liver or kidneys regarding TCPs.  
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4.3 Targeted lipopolyplexes (TLPs) 
By co-formulation strategy, TCP formulations presented different particle sizes and reduced 
surface charges as measured by DLS. These siRNA polyplexes were uniform compact 
nanoparticles without aggregates observed by TEM (Figure 3.2.3A), and siRNA complexation 
was verified by agarose gel shift assay (Figure 3.2.3B). 
 
In addition, the size of the administered siRNA polyplexes is one of the most important 
characteristics because it might affect uptake efficacy, kinetics, and internalization mechanisms 
[122]. The size limit for nanoparticles to undergo receptor-mediated endocytosis is about 100−200 
nm [123, 124]. Shape can also affect the cellular uptake of nanoparticles, for example, spherical 
particles are taken up by cells more efficiently compared with the rod-shaped particles [122]. 
 
Notably, escaping siRNA molecules from endosomes were detected by TEM and CLSM (Figure 
3.3.8), suggesting TLP1 managed to deliver siRNA into cytosol. One reasonable assumption is 
that the oligoaminoamides may act as proton sponge motifs to become increasingly cationized 
during endolysosomal acidification and, supported by the attached fatty acid domains, destabilize 
the lipid membrane [42, 125]. 
 
Most transfection reagents, e.g. RNAiMAX, Ribojuice, and Hiperfect, have a disassembly half-
life of siRNA that falls in the range of 30 min to 2 h in HeLa cells [126], suggesting the 
intracellular milieu is challenging to siRNA integrity. It has been revealed that reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) serve as messengers in cell signaling but also 
pose a potential oxidative damage to macromolecules, including nucleic acids [127]. And different 
FRET intensity profiles for certain TLP formulation in KB and L1210 cells may result from 
different reducing environments in different cell lines [128-130]. For that the rapid decrease of 
FRET intensity may relate to rapid degradation of siRNA delivered by TLP2 and TLP3, this effect 
was possibly attributed to the less potent gene knockdown. In contrast, TLP1 as the only 
formulation with 454 containing stabilizing tyrosine trimers [36, 37] improved the siRNA stability 
and thus might foster the access to the RNAi machinery.  
 
PEG as the shielding agent has been proven to be valuable in preventing non-specific interactions 
and avoiding immune recognition in the circulation [131]; however, another major barrier, liver, 
still accumulates the most of PEGylated nanoparticles [98]. In the liver, Kupffer cells recognize 
the opsonized nanoparticles via the scavenger receptor [119]. In accordance with the literature, 
 84 
 
Discussion 
abundant Cy7-siRNA of TLP1 ended up in the liver (Figure 3.3.19); besides, it is also possible 
that these fatty acid-containing siRNA polyplexes with larger size (454, TLP1 and NTLP1) were 
prone to be further metabolized by liver. In the end, recent efforts have focused on the impact of 
particle stability on the pharmacokinetic profile and gene silencing efficiency in vivo [132]. It is 
believed that the biodistribution of siRNA polyplexes is the deciding factor for better efficacy, 
thus there is an ongoing need to improve the formulation stability and following circulation time 
in the future. 
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5 Summary 
It is now widely recognized that efficient intracellular siRNA delivery to target sites in the body 
is the most important hurdle for clinical applications of RNAi [31]. Hence, to formulate siRNA 
molecules with an appropriate biocompatible delivery system is necessary for improving 
biological stability, targeted cellular uptake, and the pharmacokinetics of siRNA [133]. Herein 
different siRNA formulations were delevloped to target folate receptor (FR)-overexpressing 
tumors. 
 
In the first part, the antifolate drug methotrexate (MTX), a well-established chemotherapeutic 
agent, serves as both targeting ligand and anticancer agent, was conjugated with glutamyl units to 
the PEGylated Stp backbone. The oligomers formed uniform spherical siRNA polyplexes with a 
hydrodynamic diameter of approximately 6.5 nm. These polyplexes accessed KB cells by binding 
to the folate receptor in a MTX-dependent manner and induced efficient gene silencing activity 
in vitro. Impressively, by i.t. administration, MTX-conjugated polyplexes significantly increased 
the intratumoral retention (168 h) of the siRNA, as compared to alanine-substituted non-targeted 
control polyplexes (48 h). The combination of MTX-conjugated polyplexes and EG5 siRNA 
provided enhanced antitumoral potency with 50% of recurrence-free survival of KB tumor-
bearing mice. 
 
In the next part, we sought to improve the pharmacokinetic profile of siRNA polyplexes. To 
achieve this, we optimized the physicochemical properties of polyplexes by combinatorial 
optimization of PEGylated folate-conjugated oligomer (for FR targeting and shielding of surface 
charges) and 3-arm oligomer (for size modification and particle stability). For uni-directional fast 
coupling between the two groups of oligomers, we activated the cysteine thiol groups of one of 
the oligomers with 5,5’-dithio-bis(2-nitrobenzoic acid) to achieve a fast chemical linkage through 
disulfide formation with the free thiol groups of the other oligomer. These targeted combinatorial 
polyplexes (TCPs) were homogeneous spherical particles with favorable size and surface charge, 
which showed strong siRNA binding activity. TCPs were internalized into cells by FR-mediated 
endocytosis, triggered significant eGFP-luciferase marker gene silencing, and transfection with 
antitumoral EG5 siRNA suppressed cell proliferation in FR-expressing tumor cells. Moreover, 
the most promising formulation TCP1 after i.v. administration in L1210 tumor-bearing mice 
exhibited siRNA delivery into the tumor, resulting in 46% EG5 gene silencing at mRNA level 
without noticeable side effects.  
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Furthermore, by co-formulation of a targeted PEGylated oligomer and a lipo-oligomer, folate-
equipped targeted lipopolyplexes (TLPs) for targeted siRNA delivery were generated. TLPs 
formed spherical homogenous particles with neutralized surface charge in complex with siRNA. 
After active tumor-specific uptake via FR-mediated endocytosis, TLPs effectively unpacked 
siRNA between 2 and 4 h in response to dropping intravesicular pH, and mediated significant 
gene silencing efficiency in the target cells, as 73-88% of luciferase activity was suppressed. TLPs 
loaded with siEG5 further triggered profound EG5 gene suppression, leading to mitotic arrest and 
following strong cytotoxicity in FR-expressing tumor cells. In these formulations, tyrosine-
modified TLP1 with a diameter of 127 nm, has been proven to enable the best intracellular 
stabilization and sustained release of siRNA, thus inducing the superior gene silencing efficiency. 
By i.v. administration in L1210 tumor-bearing mice, TLP1 demonstrated tumoral retention of 
siRNA within 2 h and achieved EG5 gene silencing by 65% without noteworthy side effects. 
 
Taken together, these siRNA formulations were generated based on precise chemistry, displayed 
excellent ability for tumor-targeted delivery and gene silencing upon in vivo application, and could 
be expected to facilitate the future translation of RNAi-based nanomedicine for cancer treatment. 
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6 Abbreviations 
AGO Argonaute 
AF Alexa Fluor 
AFM atomic force microscopy 
ALT alanine aminotransferase 
AST aspartate aminotransferase 
BUN blood urea nitrogen 
CLSM confocal laser scanning microscopy 
DAPI 4',6-diamidino-2-phenylindole 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
dh hydrodynamic diameter 
DIPEA N,N-diisopropylethylamine 
DLS dynamic light scattering 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethylsulfoxide 
DODT 3,6-dioxa-1,8-octanedithiol 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DHFR dihydrofolate reductase 
DMF dimethylformamide 
DTNB 5,5-dithio-bis(2-nitrobenzoic acid) 
EphA2 ephrin type-A receptor 2 
FBS fetal bovine serum 
FCS fluorescence correlation spectroscopy 
FPGS folylpolyglutamyl synthetase 
FR folate receptor 
FRET fluorescence resonance energy transfer 
HA2 hemagglutinin subunit 2 
HBG 20 mM HEPES buffered 5% glucose pH 7.4 
HCC hepatocellular carcinoma 
HOBt 1-hydroxy-benzotriazole  
i.t. intratumorally 
i.v. intravenously 
KRAS-G12D Kirsten rat sarcoma viral oncogene homolog G12D mutation 
LMW low molecular weight 
LODER local drug eluter 
LNP lipid nanoparticle 
MPS mononuclear phagocyte system 
mRNA messenger RNA 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MTX methotrexate 
N/P pronatable amines of the oligomer/phosphates of the siRNA 
NIR near infrared 
NMP N-methyl-2-pyrrolidone 
PAMAM polyamidoamine 
PEI polyethylenimine 
PLK1 polo-like kinase 1 
PEG 
poly(I:C) 
polyethylene glycol 
polyinosinic–polycytidylic acid 
PRR pattern recognition receptors 
PTA phosphotungstic acid 
PyBOP benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
qRT-PCR quantitative real-time polymerase chain reaction 
RFC reduced folate carrier 
RISC RNA-Induced Silencing Complex 
RLU relative light unit 
ROS reactive oxygen species 
RNAi RNA interference  
RNS reactive nitrogen species 
Abbreviations 
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s.c. subcutaneously 
siRNA small interfering RNA 
Sph succinoyl-pentaethylene hexamine 
Stp succinoyl-tetraethylene pentamine 
TCEP tris(2-carboxyethyl)phosphine 
TEM transmission electron microscopy 
TIS triisopropylsilane 
TCP targeted combinatorial polyplex 
TFA trifluoroacetic acid 
TLP targeted lipopolyplex 
TLR toll-like receptor 
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